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Cocaine- and amphetamine-regulated transcript (CART), as its name implies, was 
initially identified as an upregulated transcript in response to psychostimulant 
administration.  Consequently, it has been posited to play a role in psychostimulant abuse 
and dependence.  Spurred on by the finding that a polymorphism in the CART gene was 
associated with alcoholism, we initiated studies designed to elucidate the role of CART 
peptide in alcohol dependence.  We first investigated the functional significance of 
CART peptide in alcohol dependence in vivo using a CART KO mouse.  We found that 
CART KO mice had a significant decrease in ethanol consumption that could not be 
attributed to differences in total intake, taste perception, metabolism, or sensitivity to 
ethanol.  In vitro we found that CART peptide facilitated NMDA receptor-mediated 
currents in central amygdala neurons.  Given the emerging role of CART peptide in 
anxiety and stress, we decided to examine basal and stress-induced anxiety behaviors in 
CART KO mice.  Under basal and acute stress conditions, CART KO mice did not differ 
in anxiety-like behaviors from WT mice; however, in response to a stressor, CART KO 
mice exhibited a potentiated corticosterone response.  Using chronic intermittent ethanol 
exposure (CIE), we tested CART KO and WT mice for common signs of ethanol 
dependence including an escalation of volitional consumption and the presence of 
 vii 
withdrawal-induced anxiety.  We further investigated glutamatergic neuroadaptations 
within the central amygdala of CART KO and WT mice following CIE exposure and 
early withdrawal.  CIE increased ethanol consumption and anxiety-like behaviors in mice 
of both genotypes but to a lower extent in CART KO mice.  Electrophysiologically, CIE 
enhanced spontaneous excitatory postsynaptic currents in both genotypes and decreased 
the probability of presynaptic release in WT mice only.  We believe that these 
electrophysiological neuroadaptations contribute to the development of ethanol 
dependence and may mediate withdrawal-induced anxiety behaviors.  Overall, these 
studies indicate a role for CART peptide in alcohol dependence and specifically in 
modulating ethanol withdrawal-induced anxiety.  
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Chapter 1:  
Background 
 
ALCOHOL DEPENDENCE 
Definition 
“Addiction” is a loosely used term in the popular vernacular for any behavior or 
vice that is indulged often.  Clinically, the term “dependence” is preferred over 
“addiction.”  According to the American Psychiatric Association’s fourth edition of the 
Diagnostic and Statistical Manual of Mental Disorders, alcohol dependence can be 
summarized as: 
 
A maladaptive pattern of alcohol use, leading to clinically significant impairment 
or distress, as manifested by three or more of the following seven criteria, 
occurring at any time in the same 12-month period:  1) tolerance, 2) a withdrawal 
syndrome, 3) unintended escalations in consumption, 4) inability to abstain, 5) 
increased time spent preoccupied with or seeking alcohol, 6) neglecting social or 
professional obligations to use alcohol, and 7) continued use in spite of adverse 
consequences caused by the alcohol use. 
 
With this definition in mind, the terms addict and alcoholic may be used in this 
chapter to mean any person that is dependent on alcohol.  Alcohol dependence can arise 
from persistent alcohol use alone (rarely), but more often than not other factors are 
involved.  It is estimated that up to 60% of addiction liability or predisposition to 
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addiction is inherited (Hiroi and Agatsuma, 2005).  Indeed, a number of heritable 
characteristics have been found to positively correlate with or predispose someone to the 
development alcohol dependence.  These characteristics can include novelty seeking, 
impulsivity, aggression, early onset of drinking alcohol, and poly drug use (Basiaux et al., 
2001; Bohman, 1996; Sigvardsson et al., 1996).  In fact, these latter characteristics are 
often used to define a subset of alcoholics referred to as Type II alcoholics.  Type I 
alcoholics are characterized as having few antisocial behaviors, low impulsivity, and a 
late onset of drug use (Hiroi and Agatsuma, 2005).  It has been shown that over 51% of 
Americans (18 years and older) reported using alcohol regularly (CDC, 2012).  Further, 
of those in the 18-24 age group, approximately one-third meet the criteria for alcohol 
dependence (NIAAA, 2005).  These numbers are staggering and reflect a growing 
problem in our society. 
 
Societal impact 
Alcohol abuse and dependence, as well as, complications from alcohol abuse and 
dependence make up the third leading cause of death in the United States; in fact, recent 
estimates from the CDC found that an average of 79,000 deaths and over two million 
years of potential life in the United States were lost every year (CDC, 2004).  When 
confronted with such great numbers, it is easy to overlook that each one of those deaths 
was someone’s child, sibling, or parent.  It is also easy to overlook the personal impact 
that a loved one’s death can have on his or her surviving family and friends.  While the 
enormity of these numbers seems unfathomable, they serve to illustrate the enormity of 
the problem that is alcohol dependence, but fall short of illustrating the personal impact 
that alcohol abuse and dependence can have on society.   
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There are additional health issues besides loss of life.  Heavy alcohol use can lead 
to physical impairment and increased engagement of risky behaviors.  This combination 
often leads to physical injury.  Furthermore, long-term alcohol use has been associated 
with a number of serious health issues including alcoholic hepatitis and liver cirrhosis 
(Schiff, 1997), various cancers (notably, mouth, throat, and esophagus) (Baan et al., 
2007), psychiatric issues (Castaneda et al., 1996), and coronary heart disease and stroke 
(Rehm et al., 2003).  Taken altogether, it is clear that alcohol abuse and dependence have 
significant human, personal, health, and societal impacts that warrant greater resource 
allocation to finding effective treatments. 
 
Current treatment strategies 
The current FDA-approved pharmacological treatment options for alcohol 
dependence are few and include acamprosate, disulfiram, and naltrexone.  Given the 
limited effectiveness of these compounds, additional treatments are needed.  Off-label 
use of FDA-approved drugs is the common practice or prescribing a medication for an 
unapproved indication.  Off-label use of other drugs (e.g. baclofen, topiramate, 
vareniclene) to treat alcohol dependence has yielded some promising results but these 
drugs are largely not yet proven to be effective in clinical trials specifically aimed at 
treating alcohol dependence.    
The mechanism of action for each of the FDA-approved compounds varies 
widely.  Acamprosate (Campral), for example, is a GABA analogue that was approved by 
the FDA in 2004. It has been found to decrease drinking frequency and relapse episodes 
in alcoholics (Paille et al., 1995).   Disulfiram (Antabuse), approved in 1951, is an 
inhibitor of acetaldehyde dehydrogenase.  Under normal conditions, disulfiram is without 
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any significant adverse physiological effects; however, when alcohol is consumed while 
disulfiram is present, the inhibition of acetaldehyde dehydrogenase results in the 
accumulation of acetaldehyde and severe illness ensues.  The treatment strategy for 
disulfiram is based on the idea of punishment.  Naltrexone (Revia, Vivitrol), an opioid 
receptor antagonist, was approved by the FDA in 1994 for the treatment of alcohol 
dependence (Brunton et al., 2006).  It is has been shown to reduce craving for alcohol and 
though an exact mechanism is still not known, it is thought to participate in the 
modulation of the mesolimbic dopamine system (Anton et al., 2006).   
The most commonly used off-label medications have mechanisms of action just 
as diverse as the FDA-approved drugs.  Baclofen (Lioresal, Kemstro), a GABA-B 
receptor agonist, was initially used neurologically for the treatment of spastic movement 
disorders & amyotrophic lateral sclerosis symptoms (Brunton et al., 2006).  Research in 
rodents and anecdotal case reports (including a popular autobiography by a baclofen-
assisted, recovering alcoholic and cardiologist, Olivier Ameisen, M.D., The End of My 
Addiction) prompted wider study of the effectiveness of baclofen in Europe (Ameisen, 
2008).  A one year, open study that followed over 100 patients found that baclofen was 
effective in suppressing cravings for alcohol (Rigal et al., 2012).  These results led to the 
provisional approval of baclofen by the French Agency for the Safety of Health Products 
for the treatment of alcoholism on a case-by-case basis in 2012.  A follow-up study one 
year later found that baclofen was effective in craving suppression (de Beaurepaire, 
2013).  Topiramate (Topamax) is an anticonvulsant drug approved for the treatment of 
epilepsy, migraines, and weight loss.  It has many actions including inhibition of some 
voltage dependent ion channels, enhancement of GABA-A receptor-mediated currents, 
and antagonism of some glutamate receptors (Sommer et al. 2013); unfortunately, which 
of these effects (if any) is responsible for the abstinence enhancing effect of topiramate is 
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not known.  Vareniclene (Chantix) was approved in 2006 by the FDA for smoking 
cessation.  Its mechanism of action is partial agonism of nicotinic acetylcholine receptors.  
It was recently found to reduce ethanol consumption in a preliminary clinical trial (Litten 
et al., 2013). The results are promising, but further trials with more subjects are needed to 
examine the long term use and effectiveness. 
In summary there are several FDA approved and off-label pharmacological 
options currently available, but their relatively limited efficacy in treating addicts is a 
significant hurdle.  Thus investigation into novel mechanisms of alcohol dependence are 
required to uncover potential new drug targets for the treatment of alcoholism. 
 
Models for research 
Given the great societal cost, research aimed at treating ethanol dependence is 
essential.  To that end, numerous models of ethanol dependence have been developed for 
basic research scientists studying ethanol dependence.  Two of the most popular are 
chronic ethanol treatment (CET) and chronic intermittent ethanol (CIE).  Both models 
utilize a vapor inhalation method as the route of delivery. 
CET was developed in and has been used since the late 1970s by a number of 
research groups.  Until very recently, CET was considered the standard for ethanol 
dependence induction models.  CET consists of continuous ethanol vapor exposure 
selected to yield a specific blood ethanol concentration.  The exposure period can vary in 
length, but is generally a minimum of two weeks.  This model has been found to stably 
increase voluntary ethanol consumption following withdrawal. 
Despite the success of the CET model, a continuous exposure does not really 
parallel consumption in humans.  To address this, Becker and Lopez (2004) began 
 6 
interspersing withdrawal periods into the CET model.  Eventually they came across a 
combination of ethanol vapor exposure and withdrawal that resulted in an even greater 
increase in ethanol consumption in dependent mice in a shorter time than that obtained 
with the CET model (Becker and Lopez, 2004; Lopez and Becker, 2005).  The CIE 
model has since become the standard, not only because it produces a more drastic effect 
in one-half of the time, but also because it is thought to more closely mirror human 
patterns of ethanol consumption by mimicking “binge” drinking. 
 
Anxiety, stress, and alcoholism 
The progression of alcohol dependence is often summarized with the phrase:  use, 
abuse, and dependence.  The “use” phase is characterized by drug seeking for its 
pleasurable effects.  The “abuse” phase reflects heavy usage of the drug that eventually 
leads to dependence.  Abstinence from drug use after dependence is made difficult by a 
number of factors including withdrawal symptoms.  In particular, withdrawal-induced 
anxiety is thought to play a role in mediating relapse behaviors after periods of 
abstinence.   
Alcohol dependence and anxiety are postulated to be interconnected; in fact, 
anxiety and stress are often listed as contributors to relapse in treatment seeking addicts 
(Brown et al., 1995; Sinha et al., 2011).  Furthermore, several studies have correlated a 
predisposition to anxiety disorders and subsequent substance abuse/dependence to drugs 
of abuse, including alcohol (Bekman et al., 2013; Cowley, 1992; Cox et al., 1990; 
Kushner et al., 2000a; Kushner et al., 2000b; Quitkin et al., 1972).   
One of the neurobiological effectors of anxiety (including withdrawal-induced 
anxiety) is thought to be the central amygdala (CeA).  Numerous studies have indicated 
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the importance of this brain region in alcohol dependence and withdrawal-induced 
anxiety (Dandekar et al., 2008a; Le et al., 2001; Moller et al., 1997; Pandey et al., 2003; 
Roberto et al., 2004a; Roberto et al., 2004b).  One of the most convincing of these studies 
found that lesions of the CeA, but not the basolateral amygdala, resulted in reduced 
anxiety behaviors and voluntary ethanol consumption (Moller et al., 1997).   
 
 
THE CENTRAL AMYGDALA  
Anatomy, connectivity, and role in anxiety 
The central amygdala is one of five nuclei (medial, lateral, basal and basolateral 
being the other four) comprising the amygdaloid complex (Best, 1990; LeDoux, 1992).  
The neurocircuitry of the amygdala is such that inputs from thalamus and sensory 
systems (olfactory, visual, auditory, nociceptive, etc.) innervate primarily the lateral and 
basolateral amygdala (BLA), but also the CeA (Price and Amaral, 1981).  The 
environmental information is processed and associated with somatic responses (e.g. pain) 
or reinforcing events (i.e. pavlovian conditioning stimuli).  The primary output of the 
amygdala nuclei is the CeA, which as mentioned previously receives afferent inputs from 
within the amygdala (basolateral & medial nuclei) and somatosensory systems (Price and 
Amaral, 1981).  A simplified diagramitization can be found in illustration 1.  Not 
surprisingly, this arrangement places the central amygdala in a key role for the emotional 
processing of events, as well as, a mediator or relay for a number of physiological 
processes (Best, 1990; Davis, 1992b; LeDoux, 1992).  
“Negative” emotions like anxiety, stress, and fear have profound effects on 
animals with easily observed/studied stereotypic responses; hence, most research in the 
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CeA has focused on the behaviors in the “negative” emotional spectrum.  The CeA 
projects to several brain regions involved in emotional behaviors (including anxiety, 
stress, and fear).  The following list includes some of the CeA projections with the 
associated physiological functions in parentheticals:  the lateral hypothalamus 
(tachycardia, pupil dilation), the motor nucleus of the vagus (urination, defecation), the 
midbrain central gray (freezing behaviors, social interaction, hypoalgesia), the 
paraventricular nucleus of the hypothalamus (corticosteroid release, stress responses), the 
locus coeruleus (arousal), and the substantia nigra (attention allocation) (Hopkins and 
Holstege, 1978; Davis, 1992a; LeDoux et al., 1988; Price and Amaral, 1981; Smith et al., 
2013). 
The central amygdala also has a major output pathway to the bed nucleus of the 
stria terminalis (BNST) and the nucleus accumbens (NAc) shell (Hopkins and Holstege, 
1978).  Collectively, these three regions are sometimes referred to as the extended 
amygdala complex because of their shared neuronal morphology and circuitry similarities 
(Heimer and Alheid, 1991; Hopkins and Holstege, 1978).  The extended amygdala 
complex, as a functional unit, has been implicated not only in emotional processing of 
stimuli but in drug addiction as well (Koob et al., 2013).   
Given its neuroanatomical connectivity, the CeA is poised to mediate negative 
emotional states, including anxiety, and stress responses (Davis, 1992b).  In fact, it has 
been shown that lesions of the CeA, but not the BLA, result in reduced anxiety behaviors 
(Moller et al., 1997).  Furthermore, site specific injections of the neuropeptide cocaine- 
and amphetamine-regulated transcript (CART) peptide into the CeA, but not the BNST or 
NAc, also increased anxiety-like behaviors (Dandekar et al., 2008a).  This finding is not 
unique to rodents.  Studies in primates (rhesus monkeys) have also found that specific 
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lesioning of the CeA results in a reduction of anxiety-related behaviors (Kalin et al., 
2004). 
 
Neuroadaptations in alcohol dependence  
Within the CeA, numerous neuroadaptations take place over the course of 
dependence induction.  These include changes in glutamatergic and GABAergic 
neurotransmission (Roberto et al., 2006; Roberto et al., 2004a; Roberto et al., 2004b).  
GABAergic neurotransmission in the CeA was found to be increased in ethanol 
dependent rats relative to control rats (Roberto et al., 2004a).  Interestingly, (Roberto et 
al., 2004a) glutamatergic neurotransmission and NMDA receptor expression were also 
found to be increased in rats exposed to the same chronic ethanol treatment paradigm 
(Roberto et al., 2006; Roberto et al., 2004b).  In ethanol naïve rats, ethanol was found to 
enhance GABA neurotransmission (Roberto et al., 2003).  This finding, when taken 
together with the ability of ethanol to inhibit NMDA receptors (Lovinger et al., 1989; 
Lovinger et al., 1990), supports the allostasis hypothesis that the enhancement of 
glutamatergic neurotransmission and NMDA receptors is a responsive adaptation to the 
chronic inhibitory effects of ethanol at NMDA receptors (Lovinger et al., 1989) and 
ethanol facilitated GABA neurotransmission in alcoholics.  However, upon removal of 
ethanol inhibition of NMDA receptors and ethanol-facilitated GABAergic 
neurotransmission (during abstinent periods), there is a net increase in excitatory 
glutamatergic transmission.  This increase in glutamatergic neurotransmission may 
contribute to the expression of ethanol withdrawal-induced anxiety.  A possible 
compensatory mechanism for this increased excitatory signaling might be the increased 
GABAergic inhibitory signaling observed over the same period of time (Roberto et al., 
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2004a).  This effect included increased basal release of GABA, as well as, enhanced 
inhibitory synaptic currents (Roberto et al., 2004a).   
 
 
COCAINE- AND AMPHETAMINE-REGULATED TRANSCRIPT (CART)  
Discovery, regulation, and anatomical distribution 
Cocaine- and amphetamine-regulated transcript (CART) was initially identified 
by PCR differential display as an mRNA species that was upregulated in the striatum of 
rats in response to treatment with cocaine or amphetamine (Douglass et al., 1995).  
Though somewhat controversial (Marie-Claire et al., 2003; Vrang et al., 2002), this 
general finding that psychostimulant treatment increases CART mRNA & peptide is 
widely accepted and has been repeated a number of times and under varying conditions 
(Brenz Verca et al., 2001; Fagergren and Hurd, 1999; Hunter et al., 2005).  Work by 
(Thim et al., 1999) extracted and sequenced several CART peptides from several brain 
and endocrine regions; they speculated that several of these species were intermediate 
processing products and that there were in fact only two bioactive forms of CART:  
CART 42-89 and 49-89.  These fragments are more commonly known as CART 62-102 
and 55-102.  Interestingly, only the former, shorter CART peptide is found in humans.  
Though this study is widely considered the first to discover CART peptides, a study by 
(Spiess et al., 1981) identified a “somatostatin-like polypeptide” from ovine 
hypothalamus that would later be identified as a proCART species.  
CART is highly conserved across multiple vertebrate species including a number 
of fish, porcine, bovine, rodent, amphibian, avian, and canine species.  The human (and 
rodent) CART gene encodes for three exons (with two introns) and is localized to 
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chromosome 5q13-14 in humans (Douglass and Daoud, 1996) and chromosome 13 in 
mice (Adams et al., 1999).  There is a greater than 90% homology between the human 
and rat CART genes at the nucleotide and amino acid sequences (Douglass and Daoud, 
1996).  There are a number of known transcription factor binding sites located in the 
promoter region of the CART gene including elements for CRE, estrogen receptors, 
STAT, and the AP-1 complex (Dominguez, 2006; Dominguez et al., 2002).  Notably, the 
CRE sequence form the CART gene was found to bind CREB and is thought to be the 
effector of psychostimulant induced increases in CART transcription (Barrett et al., 2002; 
Rogge et al., 2009; Xu et al., 2006).   
CART peptides are widely distributed throughout the brain.  They are generally 
expressed most prominently, however, in brain regions associated with feeding and 
energy homeostasis.  CART was first identified in the striatum of psychostimulant treated 
rats (Douglass et al., 1995).  Subsequent studies of its anatomical distribution using 
immunohistochemistry found the distribution of CART to be much more widespread and 
included several hypothalamic nuclei, the pituitary gland, and the adrenal medulla (Elias 
et al., 2001; Koylu et al., 1997).  A subsequent study from the same group using in situ 
hybridization found the distribution of CART to be even more wide spread than 
previously thought and demonstrated the presence of CART in the retina, spinal cord, 
olfactory bulbs and somatosensory cortex (Couceyro et al., 1997).  These findings were 
confirmed and extended by a third study emphasizing the presence of CART in forebrain 
structures including the nucleus accumbens, thalamus, hippocampus, and the central, 
medial, and basolateral amygdala (Koylu et al., 1998).  Subsequent studies have also 
localized CART peptides in the midbrain (Dallvechia-Adams et al., 2002) and 
sympathetic ganglia (Dun et al., 2000).  The widespread distribution of CART peptide 
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throughout the brain foreshadows the many functions that CART peptides have been 
found play physiologically. 
 
Evidence for CART as a neurotransmitter and the putative CART receptor 
The basic requirements for a protein to be classified as a neurotransmitter include 
the following:  the identification of its synthetic pathway, its presence in presynaptic 
vesicles, a postsynaptic effect, and the identification of receptor (Cooper et al., 2003).  
The synthetic pathway for CART peptides has been well characterized and begun with 
the identification of the CART gene (Dominguez, 2006; Douglass and Daoud, 1996). 
After transcription and translation, the nascent preproCART is then designated for the 
secretory pathway by a 27 amino acid signal on the N-terminus (Douglass and Daoud, 
1996; Douglass et al., 1995).  Several studies examining the ultrastructural localization of 
CART peptides using scanning electron microscopy have demonstrated that CART 
peptides are indeed present in presynaptic terminals and in large dense-core vesicles 
(Blanco et al., 2013; Smith et al., 1999; Smith et al., 1997).  CART peptides have also 
been shown to have varied postsynaptic effects.  Among the first studies to demonstrate a 
specific cellular effect of CART peptides was (Yermolaieva et al., 2001), who 
demonstrated that CART peptide could modulate the function of L-type voltage-gated 
calcium channels in the hippocampus.  Subsequent studies have found that CART 
peptides enhance the phosphorylation state of MAP kinase proteins (ERK 1 and6 2, 
specifically) (Lakatos et al., 2005), as well as, serine residues 896 and 897 of the NR1 
subunit of the NMDA receptor (Chiu et al., 2009; Chiu et al., 2010).  The final criterion, 
however, has proven more difficult.  Several research groups and studies have attempted 
to identify the CART receptor (see Vicentic et al. (2006) for review) without success; 
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however, there is some evidence to suggest the existence of a specific CART receptor.  
For example, specific CART peptide binding has been demonstrated in AtT20 cells 
(Vicentic et al., 2005), PC-12 cells (Maletinska et al., 2007), acutely prepared brain slices 
containing the hypothalamus (Keller et al., 2006), and in primary cultures of nucleus 
accumbens neurons (Jones and Kuhar, 2008).  Further studies have found that the 
putative CART receptor is likely a G-protein coupled receptor of the Gi/o family, as 
demonstrated by the pertussis toxin-sensitivity of CART peptide effects including CART 
peptide-induced phosphorylation of ERK (Lakatos et al., 2005), CART peptide 
modulation of L-type voltage-gated calcium channels (Yermolaieva et al., 2001), and 
CART peptide-mediated inhibition of FSH effects in granulosa cells (Sen et al., 2007).  
Some studies have postulated the existence of more than one CART receptor.  This idea 
is based on the different binding and relative potencies of the CART peptides in rodents, 
as well as, some minor variation in the distribution of the two bioactive CART peptides 
(Thim et al., 1999).  Evidence supporting this idea includes the finding that CART 55-
102 & 62-102 differentially modulate several behaviors including the acoustic startle 
response, inhibition of feeding, and prepulse inhibition (Bannon et al., 2001).  Taken all 
together, these studies strongly support the notion that CART peptides are indeed unique 
neurotransmitters and the existence of at least one putative CART receptor. 
 
Interactions with anxiety and stress 
CART has been repeatedly demonstrated to have anxiogenic properties (for 
review see Stanek (2006)).  In rodents, CART peptides were found to dose-dependently 
decrease open arm times in an elevated plus maze paradigm (Asakawa et al., 2001; Kask 
et al., 2000).  CART peptides administered icv have also been shown to increase anxiety 
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as measured by a decrease in social interaction time in rodents (Chaki et al., 2003).  
These results demonstrate the direct anxiogenic properties of CART peptides.  A more 
recent study, however, has demonstrated that site-specific injections of CART peptide 
into the central amygdala, but not the NAc or bed nucleus of the stria terminalis (BNST), 
produced increases in anxiety-like behaviors of rats (Dandekar et al., 2008a).  This study 
further correlated an increase in CART peptide expression in the central amygdala during 
acute withdrawal with increases in anxiety-like behaviors.  Further studies of CART 
peptides and anxiety found that icv injection of CART peptides could increase plasma 
levels of corticosterone (Smith et al., 2004). 
Acute, but not chronic, restraint stress treatment was shown to increase CART 
mRNA in the central amygdala of male rats.  Interestingly, this study also found that 
chronic restraint stress did increase CART mRNA in the dentate gyrus (Hunter et al., 
2007).  A related study found that female rats exposed to a forced swim test had a greater 
number of CART peptide containing cells in the PVN than non-stressed control rats 
(Gozen et al., 2007).   
 
CART, nociception, and the glutamate system 
Given its high level of expression in the spinal cord and specifically in the dorsal 
horn laminae (Dun et al., 2000; Koylu et al., 1998; Kozsurek et al., 2007; Ohsawa et al., 
2000), a putative role for CART in the mediation of pain was postulated.  Indeed, 
(Bannon et al., 2001) found that icv administration of CART peptides dose-dependently 
increased the paw lick latencies of mice in the hot-plate assay, implying an 
antinociceptive effect of CART peptides.  This basic antinociceptive effect of icv CART 
peptide was replicated in mice using the formalin paw lick assay (Damaj et al., 2003).   It 
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was further shown that intrathecal CART peptide administration could potentiate the 
antinociceptive actions of morphine in a tail flick latency test, which measures the latency 
of rodents to flick their tail away from a heat source (Damaj et al., 2004).  This same 
group extended their previous findings by demonstrating that intrathecal CART peptide 
administration attenuated hyperalgesia and allodynia (the reversal of pain due to a 
stimulus that would normally not provoke pain) via an opioid-independent mechanism in 
a mouse model of neuropathic of pain (Damaj et al., 2006).   
Despite all of the evidence indicating an anti-nociceptive role for CART peptide, 
there exists literature indicating a nociceptive/hyperalgesic role for CART.  It was 
reported that intrathecal administration of CART peptide decreased the latency of hind 
paw withdrawal from a heat source, suggesting that CART peptide increases sensitivity 
to heat or pain from the heat source (Ohsawa et al., 2000).   
Given the important role that NMDA receptors play in spinal cord nociceptive 
transmission, it was hypothesized that CART peptide may be interacting with NMDA 
receptors to regulate nociceptive transmission (Hsun Lin et al., 2005).  Indeed, this group 
found that administration of CART peptide potentiated the ability of intrathecal NMDA, 
but not AMPA, to increase pain sensitivity; furthermore, when they examined the 
electrophysiological effect of CART peptide on NMDA- or AMPA-induced 
depolarizations in substantia gelatinosa neurons, they found that CART peptide 
specifically potentiated NMDA-induced depolarizations while having no effect on 
AMPA-induced depolarizations (Hsun Lin et al., 2005).  Following up on this report, 
another research group confirmed the NMDA receptor potentiating effect of CART 
peptide on sympathetic preganglionic neurons in spinal cord slices; briefly, they 
iontophoretically applied NMDA in a whole-cell voltage clamp configuration before and 
after bath application of CART peptide and found that NMDA receptor-mediated 
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currents were enhanced after application of CART peptide (Dun et al., 2006).  This 
finding was extended by subsequent studies showing that the mechanism of CART 
peptide enhancement of NMDA receptor-mediated transmission was attributable to 
increases in the phosphorylation of serine residues 896 and 897 of the perquisite NR1 
subunit of NMDA receptors (Chiu et al., 2009).  They further showed that this effect was 
age-dependent (i.e. CART peptide could not enhance NMDA receptor mediated currents 
or the phosphorylation of NR1 residues ser896 and ser897 in spinal cord slices prepared 
from mice less than three weeks of age) and that pretreatment of slices with inhibitors of 
PKA or PKC (targeting residues ser897 and ser896, respectively) attenuated these effects 
(Chiu et al., 2010). 
 
CART peptides and dopamine 
CART peptides have been shown to have substantial interactions with 
psychostimulants and the brain dopamine systems.  Given its initial discovery as an 
upregulated transcript in response to cocaine or amphetamine (Douglass et al., 1995) and 
its altered gene expression in human cocaine abusers (Albertson et al., 2004) and 
overdose victims (Tang et al., 2003), CART has been the focus of several studies 
investigating psychostimulants and addiction (see Hubert et al. (2008) for review).   
Anatomically, CART peptides are present throughout the mesolimbic dopamine 
system.  In the VTA, CART peptide containing synaptic terminals have been observed 
synapsing onto dopamine neurons and GABA containing interneurons (Dallvechia-
Adams et al., 2002; Koylu et al., 1998).  In medium spiny neurons of the NAc, CART 
peptides have been observed to colocalize with prodynorphin and dopamine D1 
receptors, both markers for the direct pathway (Hubert and Kuhar, 2006).  Additional 
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studies on CART peptide localization in the NAc have shown that CART peptides are 
expressed in substance P-expressing GABAergic neurons that receive a dopamine input 
(Dallvechia-Adams et al., 2002; Hubert and Kuhar, 2005; Koylu et al., 1998; Smith et al., 
1997; Yang et al., 2005).  CART peptides have also been observed in non-mesolimbic 
dopamine systems including the arcuate nucleus of the hypothalamus (ARC) and the 
paraventricular nucleus of the thalamus (PVT) (Elias et al., 2001; Parsons et al., 2006).   
Given the common propensity of cocaine and amphetamine to increase dopamine 
release in the nucleus accumbens (Di Chiara and Imperato, 1988; Weiss et al., 1993), it 
was postulated that the psychostimulant-induced increases of CART peptides may be 
dopamine receptor-dependent.  Indeed, modulation of dopamine D3 receptors with either 
antisense oligonucleotides, dopamine D3 receptor knockout mice, or antagonists were 
found to modulate CART expression in the NAc (Beaudry et al., 2004; Hunter et al., 
2006).  The interactions of dopamine and CART, however, are not one-sided.  CART 
peptide administration (icv) has been found to increase the levels of DOPAC & HVA 
(dopamine metabolites) in the shell of the NAc (Shieh, 2003; Yang et al., 2004).  Intra-
VTA administration of CART peptide was also found to increase dopamine efflux in the 
NAc (Kuhar et al., 2005).  Furthermore, intra-VTA injections of CART peptide were 
found to produce an increase in locomotor activity that was blocked by pretreatment with 
the dopamine D2 receptor antagonist, haloperidol (Kimmel et al., 2000).  Additionally, 
intra-VTA injections of CART peptide could also produce a conditioned place preference 
(Kimmel et al., 2000).  Administration of psychostimulants typically results in increases 
in locomotor activity, however, when CART peptide is microinjected into the NAc before 
systemic psychostimulant administration, psychostimulant-induced increases in 
locomotor activity are significantly attenuated (Jaworski et al., 2003; Kim et al., 2003).  
These studies suggest a role for CART in modulating aberrant increases in dopamine 
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signaling in the NAc in response to drugs of abuse (Hubert et al., 2008; Jaworski and 
Jones, 2006; Jaworski et al., 2003; Kim et al., 2003). 
Other studies examining extra-mesolimbic dopamine systems have posited a role 
for CART peptides.  Briefly, it is has been shown that CART containing neurons of the 
ARC project to and innervate neurons of the PVT (Kirouac et al., 2006).  These neurons 
subsequently project to the NAc shell (Parsons et al., 2006).  Stimulation of glutamatergic 
afferents originating in the PVT have been shown to increase dopamine release in the 
NAc, presumably by stimulating dopaminergic presynaptic terminals (Parsons et al., 
2007).  It is therefore believed that increased CART peptide expression and release in 
response to drug-induced aberrant dopamine signaling might inhibit PVT glutamatergic 
afferents to the NAc.  Supporting this hypothesis, a study by James et al. (2010) found 
that microinjections of CART peptide into the PVT significantly decreased the number of 
active lever presses for cocaine in a drug-primed model of reinstatement.   
All together, these lines of evidence strongly suggest that CART peptides interact 
with and regulate brain dopamine systems in a meaningful way and that aberrations in 
CART peptide function in the brain may contribute to addiction processes. 
 
CART knockout mice 
Two separate mouse strains have been developed and used for studies of addiction 
(see Moffett et al. (2006) for review).  The consensus is that CART KO mice have a 
reduced propensity to consume and respond for drugs of abuse including ethanol.  One 
group, however, found no genotype differences in cocaine-induced locomotor activity or 
self administration (Steiner et al., 2006).  This finding is in direct contrast to a substantial 
study by Couceyro et al. (2005) which found that CART KO mice self administered less 
 19 
cocaine than WT mice.  This study further found reductions in a variety of 
psychostimulant related behaviors including rearing, grooming responses, locomotor 
sensitization, and conditioned place preference in CART KO mice.  A third study 
(Moffett et al., 2006) found that CART KO mice had a reduction in cocaine-, but not 
amphetamine-induced locomotor activity relative to WT mice.  Similarly, Salinas et al. 
(2012) found that CART KO mice displayed a reduction in ethanol consumption and 
preference that could not be attributed differences in total intake, taste preference, ethanol 
metabolism, or sensitivity.   
Overall, the consensus is that CART KO mice display a reduction in the 
reinforcing properties of ethanol and psychostimulants.  When taken together with the 
rest of the CART literature apropos drugs of abuse and addiction, one can presume that 
CART is critically involved in mediating the reinforcing properties of drugs of abuse. 
 
CART peptides and alcoholism 
The number of studies examining CART peptides and alcoholism are far fewer 
than those for psychostimulants.  This is surprising, given that a direct relationship 
between a CART polymorphism in intron 1 of the CART gene was strongly associated 
with alcoholism in a population of Korean males (Jung et al., 2004).  Interestingly, this 
association was unique to alcoholism and did not correlate with bipolar or schizophrenia, 
two disorders with high comorbidity with alcohol abuse.  Spurred by this finding, our lab 
examined the effect of ethanol administration on CART mRNA and peptide levels in the 
NAc.  Similar to findings with psychostimulants, we found that ethanol dose-dependently 
increased CART mRNA and peptide levels (Salinas et al., 2006).  We further found that 
pretreatment with either a dopamine D1 or D2/D3 receptor antagonist attenuated the 
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ethanol-induced enhancement of CART mRNA.  These findings were largely in accord 
with the literature examining CART and psychostimulants.  Another group found that 
exposing rats to stimuli previously associated with access to ethanol activated CART 
peptide-containing neurons in the ARC (Dayas et al., 2008).  Dandekar et al. (2008a) 
established a role for CART in ethanol withdrawal-induced anxiety with their pivotal 
study.  Briefly, they injected CART peptide into the NAc, bed nucleus of the stria 
terminalis, and the CeA and found that only injections into the CeA resulted in increased 
anxiety.  They then exposed rats to an ethanol liquid diet for two weeks to induce 
dependence and proceeded to examine ethanol withdrawal-induced anxiety.  Their 
principal finding was that central amygdala CART peptide levels positively correlated 
with ethanol withdrawal-induced anxiety.  They further found that immunoneutralization 
of CART in the central amygdala attenuated ethanol withdrawal-induced anxiety.  In a 
related study, this group also found that CART peptide levels were increased in the 
hypothalamus during withdrawal from an ethanol liquid diet (Dandekar et al., 2008b).  
Finally, a group from Australia found that icv CART peptide administration blocked 
context-induced reinstatement behaviors (King et al., 2010).  These studies, though few, 
largely support a role for CART peptides in alcoholism. 
 
 
HYPOTHESIS AND AIMS   
Overall project rationale 
It is our contention that CART peptides play a significant role in ethanol 
dependence.  Specifically, we believe that CART peptides mediate, at least in part, 
ethanol withdrawal-induced anxiety which may contribute to relapse behaviors.  Several 
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lines of evidence to that end include:  1) icv and central amygdala injections of CART 
peptide were found to be anxiogenic  (Chaki et al., 2003; Dandekar et al., 2008a), 2) 
CART peptide is strongly expressed in the CeA (a key region for anxiety behaviors), 3) 
CART peptide levels in the CeA are increased during withdrawal from chronic ethanol 
and correlate positively with withdrawal-induced anxiety (Dandekar et al., 2008a), and 4) 
immunoneutralization of CeA CART peptide blocked withdrawal-induced anxiety 
behaviors (Dandekar et al., 2008a).  We further believe that CART peptide exerts its 
anxiogenic effects by altering glutamatergic neurotransmission in the CeA.  Chronic 
ethanol has been shown to result in increased NMDA receptor expression and function in 
several brain regions, including the CeA (Roberto et al., 2004b; Roberto et al., 2006; 
Roberto et al., 2004a). This altered function in the CeA is accompanied by a 
compensatory increase in GABA neurotransmission (Roberto et al., 2004a).  The increase 
in NMDA receptor expression is likely an adaptation to the persistent inhibitory effect of 
ethanol on NMDA receptors.  Upon relief from ethanol (during withdrawal), the GABA 
system works to inhibit excessive NMDA neurotransmission and produce an anxiolytic 
effect (Koob and Le Moal, 2001).  Concurrent with these actions, CART peptide 
expression has been found to be increased in the CeA.  Given the finding that CART 
peptide potentiates NMDA receptor-mediated currents in a spinal cord preparation (Dun 
et al., 2006; Hsun Lin et al., 2005), we believe that by potentiating NMDA receptor-
mediated currents in the CeA, CART peptide opposes the anxiolytic effects of GABA 
and contributes to ethanol withdrawal-induced anxiety and dependence. 
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Specific aims 
Specific aim 1:  To investigate the effect of removal of the CART gene on ethanol 
consummatory behaviors 
 Given the previous findings that CART KO mice have a reduced propensity to 
administer cocaine (Couceyro et al., 2005) and reductions in psychostimulant-induced 
behaviors (e.g. locomotor activity, sensitization, and conditioned place preference) 
(Couceyro et al., 2005; Moffett et al., 2006), we believe that removal of the CART gene 
results in altered responses to normally reinforcing substances.  We further believe that 
this change will result in a reduced consumption or preference for ethanol. 
 
Aim 1.1:  To determine if CART KO mice will consume or prefer ethanol less than WT 
mice.  We will assess ethanol consumption and preference in CART KO and WT mice at 
a number of ethanol concentrations using a two bottle choice, unlimited access paradigm. 
 
Aim 1.2:  To compare factors known to contribute to ethanol consummatory behaviors 
between CART KO and WT mice.  If a genotype difference in ethanol consumption or 
preference is observed, we will examine bitter/sweet taste perception, ethanol metabolism 
and sensitivity to ethanol (using a loss or righting reflex assay).  Genotype differences in 
these factors could account for any observed changes in ethanol consumption. 
 
Specific aim 2:  To investigate the effects of CART peptide on glutamatergic 
neurotransmission in the central amygdala of ethanol naïve mice. 
CART has been found to potentiate NMDA receptor mediated currents in spinal 
cord preparations (Dun et al., 2006; Hsun Lin et al., 2005).  I therefore believe that 
CART will have the same effect on neurons in the CeA.  Further, the reported increase in 
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CART expression in the CeA during ethanol withdrawal (Dandekar et al., 2008a) is likely 
to have a significant impact on local glutamatergic currents.   
 
Aim 2.1:  To determine the effects of CART peptide on AMPA receptor-mediated 
spontaneous events.  Utilizing whole-cell voltage clamp recordings of mEPSCs, we will 
determine if CART peptide modulates AMPA receptor-mediated currents in a pre- or 
postsynaptic manner.   
 
Aim 2.2:  To determine the effects of CART peptide on AMPA/NMDA ratios.  Utilizing 
whole-cell voltage clamp recordings of paired eEPSCs at -80 mV and +40 mV, we will 
determine if CART peptide alters evoked AMPA or NMDA receptor-mediated currents 
and AMPA/NMDA ratios.   
 
Specific aim 3:  To investigate the effects of chronic intermittent ethanol on ethanol 
consumption, ethanol withdrawal-induced anxiety, and glutamatergic neurotransmission 
in CART KO and WT mice. 
CART has been implicated in ethanol withdrawal-induced anxiety (Dandekar et 
al., 2008a).  That study, however, failed to examine any drinking behavior associated 
with dependence.  To amend this and to expand upon their findings, chronic intermittent 
ethanol vapor exposure will be used to induce dependence.  Ethanol consumption and 
withdrawal anxiety will be assessed in CART KO and WT mice.  Finally, mice from both 
groups will be used in electrophysiological experiments examining glutamatergic 
neurotransmission in the central amygdala.   
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Aim 3.1:  To assess the efficacy of chronic intermittent ethanol vapor exposure to 
enhance ethanol consumption in CART KO and WT mice.  The chronic intermittent 
ethanol vapor treatment model has been well established and is known to induce ethanol 
dependence (Becker and Hale, 1993; Becker and Lopez, 2004; Lopez and Becker, 2005) 
including an increase in volitional ethanol consumption in a two-bottle choice paradigm.   
 
Aim 3.2:  To assess the effects of withdrawal from chronic intermittent ethanol on 
anxiety-like behaviors and HPA axis activation in CART KO and WT mice.  Chronic 
intermittent ethanol treated CART KO and WT mice will be tested in the light/dark box 
assay for anxiety-like behaviors after one and two bouts of chronic intermittent ethanol.  
Following the second bout, mice will be sacrificed and trunk bloods collected for 
determining plasma corticosterone content as a second, physiological, measure of 
anxiety.   
 
Aim 3.3:  To assess the effects of withdrawal from chronic intermittent ethanol on 
glutamatergic neurotransmission in CART KO and WT mice.  Using whole-cell voltage 
clamp recordings of sEPSCs, AMPA/NMDA ratios, and paired pulse ratios, we will 
investigate the effects of chronic intermittent ethanol on glutamatergic neurotransmission 
in CART KO and WT mice.   
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Illustration 1.  Amygdala nuclei and connections 
 
Schematic of basic amygdala microanatomy and connectivity.  The blue arrows represent 
glutamatergic projections.  The red arrows represent GABAergic projections.  BLA – 
basolateral nucleus of the amygdala, CeA – central nucleus of the amygdala, CTX – 
cortex, ICM – intercalated cell mass, LA – lateral nucleus of the amygdala, MeA – 
medial nucleus of the amygdala.  Basal nucleus of the amygdala is not shown. 
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Illustration 2.  Coronal central amygdala section illustrating the typical configuration 
used in recordings 
 
The white lines and black bars demonstrate the typical placement of the recording and 
stimulating electrodes, respectively.  The black box on the atlas image outlines the 
approximate are shown in the photograph. 
 
 
  
 27 
Chapter 2: 
Reduced ethanol consumption and preference in cocaine- and 
amphetamine-regulated transcript knockout mice 
 
ABSTRACT 
Cocaine- and amphetamine-regulated transcript (CART) is a neuropeptide 
implicated in addiction to drugs of abuse.  Several studies have characterized the role of 
CART in psychostimulant addiction, but few have examined the role of CART in alcohol 
use disorders including alcoholism.  The current study utilized a CART knockout (KO) 
mouse model to investigate the role of CART in ethanol appetitive behaviors.  A two-
bottle choice, unlimited-access paradigm was used to compare ethanol appetitive 
behaviors between CART wild type (WT) and KO mice.  The mice were presented with 
an ethanol solution (3%-21%) and water, each concentration for four days, and their 
consumption was measured daily.  Consumption of quinine (bitter) and saccharin (sweet) 
solutions were measured following the ethanol preference tests.  In addition, ethanol 
metabolism rates and ethanol sensitivity were compared between genotypes.  CART KO 
mice consumed and preferred ethanol less than their WT counterparts in both sexes.  This 
genotype effect could not be attributed to differences in bitter or sweet taste perception or 
ethanol metabolism rates.  There was also no difference in ethanol sensitivity in male 
mice; however, CART KO female mice showed a greater ethanol sensitivity than the WT 
females.  Taken together, these data demonstrate a role for CART in ethanol appetitive 
behaviors and as a possible therapeutic drug target for alcoholism and abstinence 
enhancement. 
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INTRODUCTION 
Cocaine- and amphetamine-regulated transcript is a putative neuropeptide 
transmitter found in the brain and gut.  Initially identified as an up regulated striatal 
mRNA transcript in response to systemic administration of cocaine or amphetamine 
(Douglass et al., 1995), CART has been shown to modulate a number of biological 
processes including appetite regulation, metabolism, nociception, anxiety/depression, and 
ion channel modulation (see Rogge et al. (2008) for review). 
The role of CART in drug reinforcement, while first suggested by its responsivity 
to psychostimulant administration, is further implicated by its localization to and 
interactions with numerous brain regions known to be critically important in drug 
responses (Couceyro et al., 1997; Dallvechia-Adams et al., 2002; Koylu et al., 1997).  
Furthermore, changes in CART gene expression in human cocaine abusers (Albertson et 
al., 2004) and overdose victims have been repeatedly observed (Tang et al., 2003).  
CART prominently interacts with the mesolimbic dopamine system (for review, see 
Hubert et al. (2008); for instance, icv infusions of CART appear to increase DOPAC and 
HVA levels in the shell of the nucleus accumbens (NAc) (Shieh, 2003; Yang et al., 
2004).  Conversely, the expression of CART mRNA in the NAc is directly modulated by 
dopamine receptor agonists and antagonists (Hunter et al., 2006; Salinas et al., 2006), and 
behavioral studies suggest that intracranial injections of CART into the ventral tegmental 
area produce psychostimulant-like increases in locomotor activity (Kimmel et al., 2000) 
and a conditioned place preference (CPP) (Kuhar et al., 2005).  Injections of CART into 
the NAc following systemic cocaine or amphetamine also blunt the drug-induced 
increases of locomotor activity (Jaworski et al., 2003; Kim et al., 2003).  Taken together, 
these studies strongly suggest that CART may function to significantly modulate the 
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mesolimbic dopamine system and thereby contribute to the development or expression of 
aberrant drug-seeking behaviors. 
Two CART KO mice lines have been generated and used to further investigate 
the role of CART in psychostimulant drug related behaviors.   The first line, generated by 
Asnicar et al. (2001), removed the first two exons of the CART gene and utilized a ES-
129/SvJ bacterial artificial chromosome clone injected into 129 SvJ mouse ES cells.  The 
subsequent cells were injected into C57BL6 blastocysts.  The resultant male offspring 
were crossed with C57BL6 wild type females and backcrossed to a C57BL6J 
background.  These mice appeared normal and had no gross physical abnormalities 
except that at approximately twenty weeks of age their body weights were greater than 
their wild type counterparts.  CART KO mice from the second line generated by Wierup 
et al. (2005) also displayed an increase in body weight when fed a regular diet except that 
the differences were not apparent until 40 weeks of age.  The Wierup CART KO mouse 
line was generated by removing all three of the CART gene exons and was maintained on 
an outbred, black swiss x 129SvJ background.  Both of these mouse strains have been 
used in studies examining responses to psychostimulant drugs of abuse (see Moffett et al. 
(2006) for review).  The results are mixed; one study (Steiner et al., 2006) showed no 
genotype differences in cocaine-induced locomotor sensitization or cocaine self 
administration.  However, a review by Moffett et al. (2006) which contained new data 
found a reduction in cocaine-induced, but not amphetamine-induced, locomotor activity 
in CART KO mice relative to their WT counterparts.  A third study comparing CART 
KO and WT mouse psychostimulant-related behaviors found that CART KO mice had 
diminished acute amphetamine-induced vertical activity and grooming responses relative 
to their WT counterparts (Couceyro et al., 2005).  The CART KO mice did, however, 
display an increase in locomotor activity in response to acute amphetamine.  With 
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repeated amphetamine administration, dose-dependent increases in locomotor activity 
(sensitization) were observed in CART WT, but not CART KO mice.  The authors also 
tested two doses (0.3 and 1.0 mg/kg) of amphetamine in a conditioned place preference 
(CPP) paradigm and found that CART KO mice failed to acquire a CPP response to the 
low dose of amphetamine.  Finally, Couceyro et al. (2005) also found that cocaine self-
administration was reduced in CART KO mice relative to their WT counterparts; WT 
mice had greater intake of and responding for cocaine at the majority of doses tested.  
Overall, it appears that the results from the CART KO mouse studies reflect a decrease in 
the reinforcing/rewarding properties of psychostimulant drugs in CART KO mice.  This 
conclusion is somewhat controversial, though when taken together with the CART 
literature in WT mice mentioned previously, one can generally conclude that CART is 
involved in the reinforcing properties of psychostimulant drugs of abuse. 
In contrast to the numerous studies which document the role of CART in 
psychostimulant drug reinforcement, our knowledge of CART in alcohol-seeking 
behaviors and alcoholism is limited.  (Jung et al., 2004) first provided strong evidence of 
a role for CART in human alcoholism when they documented a correlation between a 
polymorphism in intron 1 of the CART gene with alcoholism in a population of Korean 
men.  Subsequent work from our lab demonstrated a direct link between ethanol and 
CART expression.  We found that high doses of acute ethanol increase CART mRNA 
and protein in the NAc in a dose-dependent manner. Furthermore, we demonstrated that 
this increase is dependent on both D1 and D2/D3 dopamine receptors (Salinas et al., 
2006).  Work by Dayas et al. (2008) found that exposure to stimuli previously linked with 
ethanol availability activates CART-containing neurons in the arcuate nucleus as 
measured by c-fos immunoreactivity.  A role for CART in ethanol withdrawal has also 
been shown in two studies:  the first demonstrated that ethanol withdrawal induced 
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anxiety was partially mediated by increases in central amygdala CART levels (Dandekar 
et al., 2008a); whereas the second study found that CART levels in specific hypothalamic 
nuclei were increased during acute withdrawal from 15 days of a liquid ethanol diet 
(Dandekar et al., 2008b).  Furthermore, King et al. (2010) demonstrated that icv infusions 
of CART inhibit context-induced reinstatement of alcohol seeking behaviors; thereby 
strongly suggesting a role for CART in mediating the rewarding or motivational 
properties of ethanol.   
The present study sought to continue to directly examine the role of CART in 
ethanol preference and consumption.  Specifically, we examined ethanol appetitive 
behaviors in a two bottle choice, unlimited ethanol access paradigm in a CART KO 
mouse model generated by Asnicar et al. (2001).  We then examined several factors 
involved in mediating ethanol appetitive behaviors including bitter/sweet taste 
perception, ethanol metabolism, and ethanol sensitivity.   
 
MATERIALS AND METHODS 
 CART KO mice 
Three breeding trios of CART KO mice were obtained from Eli Lilly 
(Indianapolis, IN).  Their generation has been previously described (Asnicar et al., 2001).  
The progeny of these trios were bred with C57BL6J wild type mice to produce CART 
heterozygotes.  The resulting heterozygotes were further crossed to a C57BL6J WT 
background for three generations.  Heterozygotes were then crossed to produce litters 
with CART WT, heterozygote, and KO mice.  At weaning age, mice were separated by 
sex with 2-5 mice per cage.  Within one week of weaning, mice were ear labeled and tail 
biopsies collected for genotyping.  Genomic DNA was isolated from the tail biopsies 
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using the Promega Wizard gDNA kit (Madison, WI).  The purified gDNA was then used 
to genotype the mice with primers previously described by Asnicar et al. (2001).  Briefly, 
three CART primers were used; one targeting the WT allele (5’-AAG GTA GCA GTA 
GCA GCA GG-3’), one targeting a region in the mutant/CART KO allele (5’-GAA AAT 
GGC CGC TTT TCT GG-3’), and the third targeting a common fragment (5’-TAT GTG 
TAC ACG AGT GCA GG -3’) in both alleles. The predicted product sizes obtained were 
880 bp and 658 bp, respectively, for the WT and mutant/CART KO alleles.  A second set 
of actin primers (5’-GCT CGT CGT CGA CAA CGG CTC-3’ and 5’-CAA ACA TGA 
TCT GGGT CAT CTT CTC-3’; 353 bp expected product) was included in each reaction 
to serve as an internal control.  All of primers used were synthesized by Integrated DNA 
Technology (Coralville, IA).  The JumpStart REDTaq Readymix (Sigma-Aldrich, St. 
Louis, MO) was used according to the manufacturer’s protocol.  To minimize non-
specific products in the multiplex reaction, a touchdown PCR protocol was used.  The 
cycling parameters consisted of an initial 95°C denaturation cycle for 4 minutes.  Then 30  
cycles of a 30 second 95°C denaturation step, a 60°C 30 second hybridization step 
(decreasing 0.5°C every subsequent cycle), and a one minute extension step at 72°C.  An 
additional 30 cycles consisting of a 30 second 95°C denaturation step, a 30 second 45°C 
hybridization step, and one minute 72°C extension step.  A final 72°C extension step for 
seven minutes ended the protocol.  The resultant products were run on 2% agarose/TBE –
ethidium bromide gels.  The PCR was repeated for every sample to ensure the genotypes 
were correct.  Only WT and KO littermates were used in all experiments.  At 2-3 months 
of age, the mice were individually housed under a reversed 12:12 hour light schedule 
(lights on at 8 p.m.) for 3 weeks before beginning any experiments.  Food and water were 
available ad libitum.  All of the experiments were approved by the Institutional Animal 
Care and Use Committee.   
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Ethanol consumption & preference 
A continuous two-bottle choice paradigm was used to compare ethanol preference 
between WT and KO mice of both sexes.  During the acclimation period to the reversed 
light schedule and individual housing, the mice were presented with two bottles 
containing only water.  At the onset of the ethanol preference test, one of the water 
bottles was replaced with a 3% ethanol solution for four days.  After the fourth day, the 
ethanol solution was replaced with a 6% ethanol solution for four days, followed by 9, 
12, 15, 18, and 21% ethanol solutions, each following the same paradigm.  The bottles 
were removed only briefly for daily measurements of the total amounts of ethanol and 
water.  In addition, the position of the ethanol and water bottles in each cage were 
alternated daily to avoid a bottle position preference.  Mouse body weights were 
measured every other day.   
The amount of daily ethanol consumption was determined (in g/kg of body 
weight) for each animal and averaged over the four day period for each ethanol 
concentration.  Two control tubes (one with water and the other with the corresponding 
ethanol solution) were used to estimate evaporation and spillage and the consumption 
amounts obtained for experimental animals were adjusted accordingly.  Preference was 
determined by dividing the volume of ethanol solution consumed by the total volume of 
ethanol and water consumed.  Total intake of ethanol and water consumption was also 
calculated for each subject. 
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Bitter/Sweet tastant preference 
To control for any differences in bitter or sweet tastant preferences, consumption 
of quinine and saccharin solutions was assessed following the ethanol preference tests.  
After the final day of ethanol consumption, the mice were given two water tubes for two 
weeks.  The mice were then once again offered water and a non-alcohol tastant tube 
containing either a bitter (quinine) or sweet (saccharin) tastant as before (four days, 
escalating concentrations).  Quinine hemisulfate (Sigma-Aldrich) was prepared as 0.03 
and 0.06 mM solutions.  Saccharin was prepared as 0.033 and 0.066% solutions.  As 
before, the mice were weighed every other day, the consumption of each solution was 
determined daily, and the bottle position was alternated daily to control for any possible 
bottle position preference.  There was a two-week water only period between the quinine 
and saccharin tastants. 
 
Ethanol metabolism 
Ethanol naïve mice were given an i.p. injection of ethanol (2.5 g/kg, 20% solution 
in sterile PBS) between 1 p.m. and 2 p.m.  Three blood samples were collected from each 
mouse at one of the 30, 60, 120, 180, 240, or 300 minute post injection time points.  The 
blood samples were collected in heparinized capillary tubes, centrifuged at 5K rpm for 
two to three minutes (to clear the serum), and immediately used to determine blood 
ethanol content with the Pointe Scientific (Canton,  MI) enzyme assay. 
 
Ethanol Sensitivity/Loss or Righting Reflex  
Ethanol naïve male and female mice of both genotypes were tested for their 
sensitivity to ethanol with a loss of righting reflex (LORR) test.  Briefly, mice were 
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injected (i.p.) with either 3.4 or 3.8 g/kg ethanol (20% solution in sterile PBS).  The doses 
were selected because they were high enough to induce a loss of the righting reflex 
without inducing an excessively long sleep time (Blednov et al., 2006).  Fifteen to twenty 
minutes after the injection all mice were tested to ensure the righting reflex (defined here 
as the ability of the mouse to right itself three times in a thirty second period when placed 
in the supine position) was lost.  Every ten minutes after the initial loss of the righting 
reflex, the animals were tested until they had fully recovered.  One mouse failed to lose 
the righting reflex (most likely due to a misplaced injection) and was excluded from this 
study.  The experimenter testing the mice was not aware of the genotypes of the mice 
throughout the study.  All of the experiments were carried out at room temperature with 
the ethanol injection taking place between 1 p.m. and 2 p.m. 
 
Immunohistochemistry 
At the conclusion of the experiment, the mice were intracardially perfused and 
processed for CART-immunoreactivity (CART-ir) to confirm, on the protein level, the 
completion of the knockout.  Briefly, the mice were anesthetized with chloral hydrate, the 
thoracic cavity was opened and the heart freed from the pericardium, the descending 
aorta was clamped and 0.5 mL of 5,000 U/mL Heparin (Sigma-Aldrich, St. Louis, MO) 
in phosphate buffered saline (PBS) was injected into the left ventricle to prevent clot 
formation in the vasculature.  To prevent recirculation, the right atrium was cut and a 
small incision into the left ventricle allowed the insertion of the perfusion catheter.  
Saline (0.9% NaCl) containing 0.2% NaNO2 as a vasodilator was perfused for two 
minutes to clear the vasculature of any remaining blood.  This step was followed by 4% 
paraformaldehyde for 12 minutes.  The brains were then quickly excised and post fixed in 
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4% paraformaldehyde for two hours before being transferred to a 30% sucrose/PBS 
solution for at least two days.  Following this step, the brains were sectioned on a rotary 
microtome (Leica Microsystems, Bannockburn, IL) equipped with a freezing stage 
(Physitemp Instruments, Clifton, NJ).  The brains were sectioned at 40 µms and collected 
sequentially in three series.  The tissue was then stored at -20°C in a cryoprotectant 
solution (Watson et al., 1986) to maintain peptide immunoreactivity and tissue 
morphology until immunohistochemistry could be performed.   
Free floating tissue sections were rinsed six times for ten minutes with tris 
buffered saline (TBS) to remove the cryoprotectant.  To remove residual aldehydes, the 
sections were pretreated with a 1% sodium borohydrite/TBS solution for ten minutes.  
This step was followed by a one hour preincubation step in a 20% Normal Goat Serum 
(NGS), 1% hydrogen peroxide, 0.3% Triton-X 100 solution (to block nonspecific 
labeling, quench endogenous peroxide activity, and permeabilize, respectively) at room 
temperature.  The sections were then incubated in a 1/4,000 dilution of Rabbit anti CART 
(Phoenix Pharmaceuticals, Burlingame, CA) in 2% NGS, 0.3% Triton-X 100 for 48 hours 
at 4°C with gentle agitation.  After primary antibody incubation, the sections were rinsed 
with TBS four times for five minutes and then incubated in a biotinylated secondary 
antibody raised in goat directed against rabbit antibodies at a 1/200 dilution in 2% NGS, 
0.3% Triton-X 100 solution for two hours at room temperature with agitation.  After 
washing as described before, a one hour tertiary incubation with the Vectastain ABC 
Elite Kit (Vector Laboratories, Burlingame, CA) was performed according to 
manufacturer’s protocol.  The sections were washed again before labeling with a 3,3’-
diaminobenzidine (DAB; 0.8 mg/mL), 0.05% hydrogen peroxide, TBS solution for five 
minutes.  The labeling reaction was halted by rinsing the sections with TBS as described 
before.  The labeled sections were mounted onto subbed slides and allowed to dry 
 37 
overnight.  The slides were then dehydrated in an increasing gradient of ethanols, cleared 
with xylenes, and coverslipped with permount.  The slides were allowed to dry for at 
least three days.  The slides were then coded before image acquisition.  DAB stained 
images were captured using an Olympus IX-70 microscope with a Hamamatsu camera 
and Simple PCI 6 image acquisition software (Leeds Instruments, Irving, TX).   
 
Statistics 
All data are reported as the mean ± SEM.  All data were compiled into excel and 
exported to R 2.11.1 for statistical analysis.  A repeated measures, two-factor analysis of 
variance (ANOVA) was conducted to examine group differences in the ethanol drinking 
data.  Two-factor ANOVAs were conducted to examine group differences in the 
remaining experiments. 
 
RESULTS 
Genotyping & Immunohistochemistry 
Since this study is the first by our lab utilizing the CART KO mice, and given that 
the genetic knockout of the CART gene is incomplete (see (Asnicar et al., 2001) for 
details), we chose to verify the complete knockout of the CART protein using 
immunohistochemistry with an antibody directed against the full length (55-102) CART 
protein.  Our PCR genotyping results were verified in a random sample of mice used in 
the study.  We observed no CART protein expression in any brain region in the CART 
KO mice (NAc is shown in Fig. 1).  The WT mice displayed a CART-ir distribution 
similar to that previously described (Koylu et al., 1998) (Fig. 1B).   
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Figure 1.  Polymerase Chain Reaction (PCR) genotyping results and 
immunohistochemistry confirmation 
 
 
(a) Typical example of PCR genotyping results indicate the presence (or absence) of the 
wild type (WT) and cocaine- and amphetamine-regulated transcript (CART) knockout 
(KO) alleles, as well as the actin internal control bands (880, 658 and 353 bps, 
respectively).  Periodically, the PCR genotyping results were verified with 
immunohistochemistry in brain tissues using a CART antibody.  (b) The nucleus 
Accumbens (NAc) region of the brain expresses CART in the WT sample, but not in the 
CART KO sample.  ac = anterior commissure; Het = heterozygote 
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Ethanol consumption, preference, and total intake 
We observed a main effect of genotype on ethanol consumption (F(1,21)=8.4, 
p<0.01 and F(1,27)=11.7, p<0.01, for males & females, respectively) such that, CART 
KO mice (of both sexes) consumed less ethanol than their WT counterparts (Figure 2A & 
B).  Total intake did not differ between genotypes (Figure 2C & D).  Ethanol preference 
was altered in the CART KO mice such that they also preferred ethanol less than their 
WT counterparts (F(1,21)=6.2, p<0.01 and F(1,27)=4.4, p<0.01, for males and females, 
respectively; Figure 2E & F).    
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Figure 2.  CART KO mice display reduced consumption and preference of ethanol 
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Male CART KO mice consumed less EtOH than their wild type (WT) counterparts (A & 
E, respectively), but did not differ in their total liquid intake (C).  Female CART KO 
mice also consumed and preferred less EtOH than their WT counterparts (B & F, 
respectively) and had similar levels of total liquid intake to the WT mice (D).  n = 11 per 
genotype for males and n = 14 per genotype for females.  *P<0.05; **P<0.01. 
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Bitter/Sweet tastant preference, ethanol metabolism, and sensitivity 
There was no effect of concentration or genotype on saccharin (Figure 3A and B) 
or quinine consumption (Figure 3C and D).  There was no effect of sex or genotype on 
ethanol metabolism.  Both male (Figure 4A) and female (Figure 4B) mice reached a peak 
BEC of approximately 60 mM within the first hour after the injection.  Five hours after 
the injection, the BEC of the mice returned to basal levels.  There was no main effect of 
ethanol dose on ethanol sensitivity, as measured by the duration of the LORR.  There was 
also no genotype effect in male mice (Figure 5A); however, in female mice, a genotype 
effect was observed such that CART KO mice had a longer duration of the LORR at both 
of the ethanol doses (F(1,27)=2.9, p<0.01; Figure 5B).  
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Figure 3.  Removal of the CART gene does not alter taste preference for bitter or sweet 
tastants 
 
 
 
 
Removal of the cocaine- and amphetamine-regulated transcript gene does not alter taste 
preference for saccharin (a & b, respectively, for males and females) or quinine (c & d, 
respectively for males and females) tastants.  n = 11 per genotype for males and n = 14 
per genotype for females.  WT = wild type; KO = knockout 
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Figure 4.  The metabolism of ethanol did not differ between CART KO and WT mice. 
 
 
 
The metabolism of ethanol did not differ between cocaine- and amphetamine-regulated 
transcript knockout (KO) and wild type (WT) mice in male (A) or female (B) mice.  n = 7 
per genotype for males and n = 8 per genotype for females.  BEC = blood ethanol content 
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Figure 5.  Sensitivity to ethanol does not differ between genotypes in male mice 
 
 
 
There was no difference in ethanol sensitivity between cocaine- and amphetamine-
regulated transcript (CART) knockout (KO) and wild type (WT) male mice (a).  In 
females, however, the CART KO mice had an increased loss of righting reflex (LORR) 
duration compared with their WT counterparts (b).  n = 6 per genotype for males and n = 
7 per genotype for females.  *P<0.05 
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DISCUSSION 
This constitutes the first report that removal of CART protein is accompanied 
with a decrease in ethanol consumption and preference behaviors that cannot be 
attributed to differences in taste perception, ethanol metabolism, or ethanol sensitivity.  
Most notably, these data are in direct accord with previous work that reduction of CART 
expression reduces cocaine self-administration, but not of sweet tastants (Couceyro et al., 
2005).  In light of the fact that non-drug rewards are not affected by removal of the 
CART gene, this consistent response to both ethanol and psychostimulants is strongly 
suggestive that CART expression is functionally significant in a variety of drug-seeking 
states.  Behavioral and pharmacological studies examining the role of CART in drug 
reinforcement indicate that CART itself is reinforcing.  Kimmel et al. (2000) and Kuhar 
et al. (2005) found that intra-VTA injections of CART produce psychostimulant-like 
behavioral effects (including dose-dependent increases in locomotor activity and 
conditioned place preference) and increase dopamine release in the NAc.  It is therefore 
possible that without this agonist-like activity of CART in the VTA (which would be 
increased in response to drug administration), the reinforcing properties of drugs of abuse 
are mitigated or occluded, resulting in the observed decrease of drug and ethanol 
consumption in CART KO mice reported here and previously (Couceyro PR, 2005; 
Couceyro et al., 2005).   
The reduced consumption and preference for ethanol observed in CART KO mice 
of both sexes supports the aforementioned theory.  The genotype difference in preference 
and consumption cannot be attributed to differences in total liquid intake between 
genotypes.  Therefore, other factors known to contribute to ethanol appetitive behaviors 
were examined.  It is possible that the palatability or taste preference of ethanol differs 
between CART KO and wild type mice; however, in our studies, we observed no 
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differences in the consumption of saccharin or quinine solutions, suggesting that there 
were no differences in taste preference between genotypes.  We next compared the 
metabolism rates in CART KO and WT mice to assess whether or not the differences in 
ethanol consumption and preference could be accounted for by a decrease in ethanol 
metabolism rate in CART KO mice.  Mice of both sexes and genotypes received a 2.5 
g/kg i.p. dose of ethanol and blood samples were collected and assayed for blood ethanol 
content across a number of time points.  There was no difference in the time-matched 
blood ethanol concentrations between genotypes, suggesting no differences in ethanol 
metabolism rates.  Given the known role of CART in feeding, metabolism, and energy 
homeostasis, the lack of a CART KO effect on the ethanol metabolism rate was 
surprising (see Rogge et al. (2008) for review).  It is also noteworthy that contrary to 
previous reports, no significant differences in body weight were observed between 
genotypes in any of the experiments.  The lack of a body weight difference could be 
attributed to the fact that these studies were all conducted on mice that were at most 25 
weeks old.  Previous studies of genetically modified mice have shown a negative 
relationship between the latency to recover the righting reflex and ethanol consumption 
(Thiele et al., 1998).  We therefore examined the ethanol sensitivity of CART KO and 
wild type mice using the loss-of-righting-reflex assay.  The reduced consumption of 
ethanol could be attributed to a relative increase in ethanol sensitivity; indeed, in female 
mice we observed a genotype effect such that CART KO mice had an increased 
sensitivity to the doses of ethanol tested here. However, we observed no such difference 
in ethanol sensitivity between male CART KO and wild type mice.   
Another CART-rich brain region shown to be important for ethanol consumption, 
the Edinger-Westphal nucleus (Bachtell et al., 2004), was recently shown to have a 
significantly reduced expression of CART in the low alcohol-drinking DBA/2J mouse 
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strain relative to the high alcohol-drinking C57BL6J mouse strain (Giardino et al., 2012).  
These results further support a role for CART in ethanol consumption and strengthen the 
main finding of the current study that null (or low) levels of CART are associated with 
reduced ethanol consumption. 
It should be noted that the use of global CART knockout mice leaves open the 
possibility for unforeseen compensatory effects in CART-related neurotransmitter 
systems that could account for the differences in ethanol consumption and preference 
observed.  Throughout this study, no gross abnormal physiology or behaviors were 
observed in any of the CART KO mice.  Additionally, a preliminary study (Couceyro PR, 
2005) using a second CART KO mouse reported results similar to those described in the 
current study with two exceptions, the CART KO mice in that study were on a different 
background strain than the mice in this study and had a greater total fluid intake than their 
wild type counterparts.  Nonetheless, the overall finding that CART KO mice consumed 
and preferred ethanol less than their WT counterparts is consistent with the findings in 
our study.   
An alternative (or additional) role for CART suggested by the literature posits that 
CART acts as a homeostatic mechanism to curtail excessive dopamine signaling (in 
response to psychostimulant administration) in the NAc (Hubert et al., 2008; Jaworski 
and Jones, 2006; Jaworski et al., 2003; Kim et al., 2003).  These studies have focused on 
the mesolimbic dopamine system; however, other studies have investigated the role of 
thalamic and hypothalamic CART in regulating NAc dopamine signaling and drug 
related behaviors.  The arcuate nucleus (ARC) is a CART-neuron rich region that projects 
to the neurons of the paraventricular thalamus (PVT) (Kirouac et al., 2006) which in turn 
project to the NAc shell (Parsons et al., 2006).  Stimulation of the PVT (and its 
glutamatergic afferents) has been shown to increase NAc shell dopamine levels 
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independent of VTA activity, presumably by activating presynaptic dopamine terminals 
in the NAc (Parsons et al., 2007).  It has been previously reported that in a reinstatement 
model of relapse, stimuli previously linked to ethanol activated CART neurons in the 
ARC (Dayas et al., 2008).  Given that CART neurons in the ARC project to and appose 
PVT neurons, and that PVT neurons subsequently project to and modulate dopamine 
levels in the NAc, it is not unexpected that CART in the PVT could modulate drug-
related behaviors.  Indeed, James et al. (2010) found that injections of CART into the 
PVT dose-dependently decreased active lever pressing for cocaine in a drug-primed 
reinstatement model.  Taken together, a common mechanism for CART as an inhibitor of 
aberrant dopamine signaling in response to drugs of abuse begins to form.  Thus, one 
would expect that CART KO mice may readily engage in uncontrolled drug intake 
(without a negative or inhibitory feedback signaling system in response to high or binge 
doses of drugs).  However, this is not what we observed in this study.  It is likely that the 
role of CART in mediating the reinforcing/rewarding effects of drugs of abuse is more 
complex than behavioral studies in rodents would seem to indicate and warrants further 
investigation.   
In summary, the present study demonstrates a role for CART in ethanol 
consummatory behaviors; moreover, we demonstrated that removal of the CART gene 
reduced volitional ethanol consumption in mice in a manner that cannot be attributed to 
altered intake levels, taste preference, ethanol metabolism, or ethanol sensitivity (at least 
in males).  Further research aimed at exploring and understanding exactly how the CART 
system is involved in addiction (and alcoholism) and how the removal of CART was able 
to reduce ethanol consumption is necessary.  Future behavioral, biochemical, and 
electrophysiological studies will elucidate the mechanism(s) by which CART exerts its 
effects on ethanol consumption and its potential role in mediating the reinforcing effects 
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of drugs of abuse.  The findings of this study imply a role for CART in drug 
reinforcement and as a potential therapeutic drug target that may reduce volitional 
ethanol intake or enhance abstinence.   
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Chapter 3: 
Central amygdala CART modulates ethanol withdrawal induced 
anxiety 
 
ABSTRACT 
Ethanol withdrawal-induced anxiety is a common contributing factor to relapse 
behaviors.  A key locus of ethanol withdrawal-induced anxiety is the central nucleus of 
the amygdala, which in addition to its role in stress and anxiety, has also been shown to 
be critically involved in ethanol consumption and dependence.  The central amygdala 
neuropeptide, cocaine- and amphetamine-regulated transcript (CART), is anxiogenic and 
has recently been implicated in mediating ethanol withdrawal-induced anxiety, which is 
among the most common contributing factors to relapse in ethanol dependence.  We 
recently acquired a CART KO mouse line and found a reduction in ethanol preference 
and consumption.  Given the role of CART peptide in ethanol consumption and in 
mediating ethanol withdrawal-induced anxiety, the current study sought to characterize 
the effect of chronic intermittent ethanol vapor exposure (CIE) on ethanol consumption, 
withdrawal-induced anxiety and stress, and glutamatergic neurotransmission in the 
central amygdala of CART KO mice.  We additionally sought to determine the cellular 
mechanism through which CART peptide may exert its anxiogenic effects.  To that end, 
we studied the effect of CART peptide on glutamatergic transmission in central amygdala 
neurons and found a reduction in AMPA/NMDA ratios with no change in the AMPA 
component, suggesting that CART peptide enhances NMDA receptor-mediated 
neurotransmission.  We then characterized basal and acute stress-induced anxiety-like 
behaviors with the light/dark box assay and found no difference between CART KO and 
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WT mice under basal or acute stress-induced conditions.  We did, however, observe a 
potentiated corticosterone response to an acute stressor in CART KO mice.  We then 
proceeded to induce ethanol dependence using a chronic intermittent ethanol vapor model 
(CIE) and found that a single bout of CIE treatment resulted in escalated ethanol 
consumption and anxiety-like behaviors in both CART KO and WT mice with statistical 
trends towards a reduction in ethanol consumption in CART KO mice.  We further found 
that following two bouts of CIE treatment, anxiety-like behaviors were differentially 
altered such that CART KO mice displayed a reduction in anxiety-like behaviors relative 
to WT mice; however, the plasma corticosterone levels were similar between genotypes.  
Electrophysiologically, we found an enhancement of AMPA receptor-mediated sEPSCs 
in CIE treated mice of both genotypes.  Moreover, we found no CIE or genotype induced 
differences in AMPA/NMDA ratios.  Finally, we found an increase in paired pulse ratios, 
suggesting a decrease in presynaptic release probability, of CIE-treated WT mice.  These 
combined findings support the importance of CART peptide in ethanol withdrawal-
induced anxiety behaviors and ethanol dependence and posit a mechanism for the 
anxiogenic effects of CART in the central amygdala.  Furthermore, they implicate 
distinct pre- and postsynaptic glutamatergic neuroadaptations in ethanol dependence.   
 
 
INTRODUCTION 
Cocaine and amphetamine regulated transcript (CART) has been implicated in a 
number of biological processes including addiction and anxiety/stress.  As its name 
suggests, CART was initially identified as an upregulated striatal transcript in response to 
psychostimulant administration (Douglass et al., 1995).  Subsequent study of CART has 
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found that it may play a role in mediating the reinforcing properties of drugs of abuse as 
evidenced by its ability to produce a conditioned place preference (CPP) and increased 
locomotor activity when injected into the ventral tegmental area (VTA) (Kimmel et al., 
2000; Kuhar et al., 2005).  Furthermore, intracerebroventricular (icv) administration of 
CART peptide has been shown to increase dopamine turnover in the nucleus accumbens 
(NAc) (Shieh, 2003; Yang et al., 2004), suggesting an increase in dopaminergic activity.  
Further still, studies using CART knockout mouse models have shown:  a reduction in 
cocaine-induced locomotor activity (Moffett et al., 2006), a reduction in amphetamine-
induced CPP and locomotor sensitization (Couceyro et al., 2005), a reduction in 
consumption and preference for ethanol (Salinas et al., 2012), and reduced self 
administration of cocaine (Couceyro et al., 2005).  Taken together with studies 
demonstrating dopamine receptor modulation of CART expression and protein levels 
(Hunter et al., 2006; Salinas et al., 2006), as well as, reports of altered CART expression 
in the VTA and NAc of overdose victims and cocaine abusers, respectively, a role for 
CART peptide in addiction can be assumed (Albertson et al., 2004; Tang et al., 2003).   
A role for CART in anxiety and stress has also been shown.  An acute restraint 
stress was shown to increase CART mRNA in the central amygdala of adult male rats 
and in the dentate gyrus of chronically restrained rats (Hunter et al., 2007).  Female rats 
had a greater number of CART peptide positive cells in the paraventricular nucleus of the 
hypothalamus following a forced swim test than non-stressed rats (Gozen et al., 2007).  
Further lines of evidence indicating a direct role for CART peptide in anxiety and stress 
include icv injection studies of CART peptide demonstrating:  1) increased plasma 
adrenocorticotropin hormone and corticosterone (Smith et al., 2004), 2) decreased time 
spent in the open arms of the elevated plus maze (Kask et al., 2000), and 3) decreased 
social interaction time in rats (Chaki et al., 2003). 
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Despite all of the research centered on CART peptide and anxiety and stress, an 
exact mechanism of how CART peptide produces its anxiogenic effects is not known.  
One basic research study found increased CART peptide levels in the central amygdala of 
rats undergoing withdrawal from chronic ethanol and correlated the increased CART 
with elevated ethanol withdrawal-induced anxiety (Dandekar et al., 2008a).  The same 
study found that reducing the amount of CART peptide in the central amygdala, 
specifically, attenuated alcohol withdrawal-induced anxiety.  This finding was the first to 
implicate CART peptide in the central amygdala (a region well known to be involved in 
addiction and anxiety and stress) as a contributor to alcohol withdrawal-induced anxiety.  
Like previous studies, however, this report did not investigate the mechanism for how 
CART peptide may modulate anxiety.  To that end, this study sought to determine a 
mechanism for how CART peptide administration could be effecting increases in 
anxiety-like behaviors.  A review of the literature reveals that CART peptide enhances 
NMDA receptor-mediated transmission by increasing phosphorylation at the ser896 and 
ser897 residues of the perquisite NR1 subunit of NMDA receptors (Chiu et al., 2009; 
Chiu et al., 2010; Dun et al., 2006; Hsun Lin et al., 2005).  We posit that this 
enhancement of NMDA receptor-mediated transmission may be the mechanism through 
which CART peptide exerts its anxiogenic effects; therefore, we examined the effect of 
CART peptide on glutamatergic transmission in the central amygdala. 
Interestingly, addiction and anxiety are thought to be interconnected; indeed, 
anxiety and stress are often listed as contributors to relapse in treatment seeking addicts 
(Brown et al., 1995; Sinha et al., 2011).  Also, a number of studies have positively 
correlated a person’s predisposition to anxiety disorders and subsequent addiction to 
drugs of abuse, including alcohol (Bekman et al., 2013; Cowley, 1992; Cox et al., 1990; 
Kushner et al., 2000a; Kushner et al., 2000b; Quitkin et al., 1972).   
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Given the relationships between CART peptide, anxiety, and ethanol dependence, 
we hypothesized that CART KO mice would be resistant to ethanol withdrawal-induced 
anxiety and escalations in ethanol consumption induced by chronic intermittent ethanol 
(CIE) exposure (which has been shown to result in an ethanol withdrawal phenotype and 
enhance ethanol consumption (Becker and Hale, 1993; Becker and Lopez, 2004; Lopez 
and Becker, 2005)).  We further hypothesized that alterations in glutamatergic signaling 
in the central amygdala would accompany ethanol dependence and be absent or 
attenuated in CART KO mice.  Therefore the present study sought to (1) compare basal 
anxiety states between CART KO and WT mice, (2) examine stress responsivity in 
CART KO mice, (3) determine the effects of acute CART peptide on central amygdala 
neurons, (4) determine if CART peptides are necessary for CIE treatment to increase 
ethanol consumption, (5) examine anxiety and stress levels during early withdrawal from 
CIE, and (6) determine the electrophysiological consequences of CIE and early 
withdrawal on glutamatergic synaptic transmission in the central amygdala. 
 
 
MATERIALS & METHODS 
Subjects 
The mice used for the acute restraint stress studies were eight to ten week old, 
male C57BL6J mice from the Jackson Laboratory (Jackson Labs, Bar Harbor, ME).  
Upon arrival at the University of Texas Animal Resources Center, the mice were housed 
up to four per cage and allowed to acclimate for one week prior to transport to the 
laboratory vivarium.  Once at the laboratory vivarium, the mice were individually housed 
 56 
and allowed to acclimate to the reversed light cycle for a three week period before the 
initiation of any studies.   
The mice used for the electrophysiological studies of acute CART peptide effects 
on central amygdala glutamatergic activity were also ordered from the Jackson 
Laboratory.  These mice were also males and ordered to be three to four weeks old at the 
time of arrival at the Animal Resources Center.  The mice were housed up to four per 
cage and allowed to acclimate for at least three days before being moved to the laboratory 
vivarium.  Once there, the mice were allowed to acclimate for one week before being 
used in experiments.   
The generation of the CART KO mice used in these studies has been previously 
described (Asnicar et al., 2001; Salinas et al., 2012).  Briefly, CART KO mice were 
obtained from Eli Lilly (Indianapolis, IN) and bred with C57BL6J wild type mice to 
produce CART heterozygotes.  These CART heterozygotes were further back crossed 
with C57BL6J mice for three generations.  Heterozygote crosses were used to produce 
CART KO and WT littermates for experiments and heterozygote pups were used as 
breeders.  At 21-23 days of age, mice were weaned and separated by sex with no more 
than five mice per cage.  At the time of weaning, mice were ear labeled and a tail biopsy 
was collected for genotyping.  Genomic DNA was isolated using the Promega Wizard 
gDNA kit (Madison, WI) and used to PCR genotype the mice as described by Asnicar et 
al. (2001) with the addition of an internal control described in Salinas et al. (2012).  
Three CART primers were used:  one targeting the WT allele (5’-AAG GTA GCA GTA 
GCA GCA GG-3’), a second targeting a region in the KO allele (5’-GAA AAT GGC 
CGC TTT TCT GG-3’), and the third targeting a fragment (5’-TAT GTG TAC ACG 
AGT GCA GG -3’) common to both alleles.  The product sizes for each of the primer sets 
were 880 bp for the WT allele and 658 bp for the CART KO allele.  A set of actin 
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primers (5’-GCT CGT CGT CGA CAA CGG CTC-3’ and 5’-CAA ACA TGA TCT 
GGGT CAT CTT CTC-3’; 353 bp expected product) was included in each reaction to 
serve as an internal control.  The primers were synthesized by Integrated DNA 
Technology (Coralville, IA).  The JumpStart REDTaq Readymix (Sigma-Aldrich, St. 
Louis, MO) was used according to the manufacturer’s protocol.  A touchdown PCR 
protocol that consisted of an initial 95°C denaturation cycle for 4 minutes.  Then 30  
cycles of a 30 second 95°C denaturation step, a 60°C 30 second hybridization step 
(decreasing 0.5°C every subsequent cycle), and a one minute extension step at 72°C.  
Thirty additional cycles consisting of a 30 second 95°C denaturation step, a 30 second 
45°C hybridization step, and a one minute 72°C extension step.  A final 72°C extension 
step for seven minutes followed.  The products were separated on 2% agarose/TBE –
ethidium bromide gels.  Each sample was run in duplicate reactions to ensure the 
genotypes obtained were correct.  At 10-12 weeks of age, male mice to be used 
experimentally were moved to a laboratory vivarium and  individually housed under a 
reversed 12:12 hour light schedule (lights off at 12 p.m.) for 3 weeks before beginning 
any experiments.   
Food and water were available ad libitum to all of the mice in all of the 
experiments.  All of the experiments were approved by the Institutional Animal Care and 
Use Committee of the University of Texas at Austin and are consistent with the 
guidelines of the NIH guide for the Care and Use of Laboratory Animals.   
 
Experimental design 
The overall study design involved five main experiments intended to elucidate the 
effects of CART peptide on central amygdala neurons, examine anxiety-like behaviors in 
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CART KO and WT mice, and to examine the effects of chronic intermittent ethanol 
exposure on anxiety-like behaviors and electrophysiological properties of central 
amygdala neurons in CART KO and WT mice.   
The first experiment aimed to determine the effects of CART peptide on 
glutamatergic activity in central amygdala neurons of C57BL6J mice with the hope of 
demonstrating in our hands that application of CART peptide would enhance 
glutamatergic activity in the central amygdala and serve as a potential cellular mechanism 
for the anxiogenic effects of CART peptide reported by others (Chaki et al., 2003; Kask 
et al., 2000; Dandekar et al., 2008a).  This was achieved by electrophysiologically 
examining excitatory post synaptic currents (EPSCs) and AMPA/NMDA receptor 
mediated ratios of central amygdala neurons.   
The second experiment aimed to validate the light/dark box assay as a suitable 
method for assessing anxiety-like behaviors in our hands.  To this end, adult male, 
C57BL6J mice were exposed to an acute restraint stress or a clean novel cage as a control 
and then tested in the light/dark box.  Following the behavioral trial in the light/dark box, 
the mice were sacrificed and plasma corticosterone content assessed with an ELISA as a 
secondary, physiological measure of anxiety.   
The third experiment aimed to determine if removal of the CART gene would 
result in a reduction of basal anxiety-like behaviors in CART KO mice relative to CART 
WT mice using the light/dark box.   
The fourth experiment aimed to determine if stress responsiveness was altered in 
CART KO mice relative to CART WT mice.  This was determined by acutely restraining 
adult male mice of both CART genotypes and then assessing anxiety-like behavior using 
the light/dark box.  Immediately following the behavioral trial in the light/dark box, these 
mice were sacrificed and their plasma corticosterone content was assessed as before with 
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an ELISA.  Non-stressed control groups were run concurrently with the acute restraint 
stress groups for each genotype.   
The fifth experiment was a comprehensive study examining the effects of early 
withdrawal from chronic intermittent ethanol on ethanol consumption, anxiety-like 
behavior, plasma corticosterone, and basic electrophysiological properties of 
glutamatergic signaling in the central amygdala in CART WT and KO mice.  These aims 
were accomplished by measuring ethanol consumption before and after a bout of chronic 
intermittent ethanol vapor, measuring anxiety-like behaviors using the light/dark box and 
plasma corticosterone with an ELISA, and electrophysiological measures of spontaneous 
glutamatergic activity, AMPA/NMDA receptor mediated ratios, and paired pulse ratios.  
Air vapor control mice of both genotypes were run in parallel with the chronic 
intermittent ethanol treated mice and examined for the same parameters as the 
experimental mice.   
 
Acute restraint stress 
For the acute restraint stress studies, individually housed mice were restrained 
with a DecapiCone™ (Braintree Scientific, Braintree, MA), a triangular, heavy plastic 
cone with an open tip for the mice to breathe.  A binder clip was used to secure the open 
end and ensure that the mouse remained in the DecapiCone™.  Each restraint stress 
session lasted ten minutes and was carried out in ambient room light on a 3D rotator 
rotating at 10 rpm.  Fecal boli deposited in the DecapiCone™ were counted.   
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Light/dark box behavioral assay 
Anxiety-like behaviors were assessed using the light/dark box assay (for review 
see Bourin and Hascoet (2003)) which is designed to exploit rodents’ natural aversion to 
brightly lit areas.  The light/dark box used in this study (Stoelting Co., Wood Dale, IL) 
consists of two plexi glass compartments – one clear and the other darkened – measuring 
20.5 x 40 x 35 cm (W x D x H) and 19 x 40 x 35 cm, respectively, with an opening for 
mouse movement between the two compartments.  The light/dark box was contained (and 
behavioral experiments run) in a custom-built sound attenuation cubicle with an LED 
ceiling lamp centered over the “light” side of the light/dark box, a ventilation port, a fan 
for air circulation, and a camera port in the ceiling for video recording of the behaviors.   
For the acute restraint stress studies, each behavioral trial was carried out 
immediately following the end of the restraint stress period.  For the chronic intermittent 
ethanol studies, each behavioral trial was carried out approximately six and a half hours 
into the withdrawal periods.   
Each behavioral trial was ten minutes in duration and began with the mouse being 
placed in the center of the light compartment of the light/dark box.  The behavioral trial 
was video recorded with a Sony digital video camera and analyzed offline by two 
reviewers blind to the treatment conditions of each mouse.  Several parameters were 
scored including:  the latency time for the first entry into the dark compartment, the 
number of transitions between the two compartments, the amount of time spent in the 
light and dark compartments, the number of rears, and the number of fecal boli.  The 
scores from the two reviewers were averaged and used for statistical analysis.  In the rare 
circumstance that the scorers differed by more than 10%, a third reviewer, also blind to  
the treatment conditions, was asked to review the video in question and the two scores 
closest in value to each other were used for statistical analysis.  Immediately following 
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each trial the light/dark box was cleaned with a 5% bleach solution and then with a soapy 
water solution.  For the acute restraint stress tests, the chambers were allowed to dry after 
cleaning for at least 25 minutes between mice/trials.  Only one mouse per day was tested 
for the chronic intermittent ethanol study so the chambers were allowed to dry overnight 
after cleaning.  Four mice that displayed little to no locomotion, consequently spending 
the entire behavioral trial in the light compartment, were excluded from their respective 
studies.  One mouse in the chronic intermittent ethanol study displayed seizure-like 
activity and was removed from the study.   
 
Corticosterone ELISA 
In the acute restraint stress experiments, mice were sacrificed by rapid 
decapitation under isoflurane anesthesia immediately following the light/dark box assay.  
The trunk bloods were collected and centrifuged at 14,000 rpm at 4°C for 6 minutes.  The 
plasma was then isolated with a glass Pasteur pipette, divided into four equal aliquots of 
at least 50 µLs each, and stored at -20°C until the corticosterone ELISA could be run.  
For the chronic intermittent ethanol study, following the light/dark box assay, mice were 
rapidly decapitated under isoflurane anesthesia and the trunk bloods collected and kept on 
ice until brain tissues could be harvested and sliced for electrophysiology experiments 
(approximately 25 minutes).  The trunk bloods were then processed in a similar fashion 
to the trunk bloods from the acute restraint stress study.   
Plasma corticosterone levels were assayed in control and experimental mice using 
the Corticosterone ELISA kit (Enzo Life Sciences, Plymouth Meeting, PA).  For the 
assay, plasma samples were thawed and mixed with a steroid displacement reagent (39:1 
ratio, sample to reagent) provided in the kit to free all corticosterone in the sample from 
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any binding proteins in the plasma.  The samples were then diluted in a 39:1 ratio with 
assay buffer before running the ELISAs.  This sample dilution ratio was determined 
empirically to yield the greatest recovery of corticosterone while still falling within the 
dynamic range of the assay.  The corticosterone ELISA was then carried out according to 
the manufacture’s recommended protocol.  Once the assay was completed, the microplate 
was scanned at 405 nm using a VictorX microplate reader (PerkinElmer, Waltham, MA) 
and the results were exported and saved to an Excel spreadsheet.   
The corticosterone ELISA results were then analyzed online with the 
immunoassay software package, MyAssays (www.myassays.com), and the specific 
module for the Enzo Life Sciences Corticosterone kit.  This module utilizes a four 
parameter logistic curve fit for the standard curve generation and sample concentration 
determination (expressed as pg/mL).  The average intraassay variability was 5.5% and the 
interassay variability was 13.1%.   
 
Two bottle choice ethanol drinking 
During the acclimation period to the reversed light schedule and individual 
housing in the laboratory vivarium, the mice were presented with two bottles containing 
only water.  Then a limited access, two-bottle choice paradigm was used to determine 
daily ethanol consumption for a three week period.  At 11:30 (30 minutes before the 
beginning of the dark cycle), the normal water bottles were replaced with two bottles, one 
containing a 15% ethanol solution and the second containing water, for two hours.  At the 
end of the two hour period, the new ethanol and water bottles were removed and the 
normal water bottles were replaced.  Beginning on the fifteenth day (the start of the third 
week), after the two hour drinking period, the ethanol and water bottles were weighed 
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and ethanol consumption was calculated for each mouse.  The amount of daily ethanol 
consumption was determined (grams of ethanol per kilogram of body weight) for each 
animal and averaged over the final five day period to establish the baseline ethanol 
consumption levels.   
Following three days of withdrawal from chronic intermittent ethanol or control 
vapor exposure (see below), the mice were once again allowed to consume ethanol daily 
for a two hour period as before for five consecutive days to determine if the CIE vapor 
exposure would affect ethanol consumption.   
The position of the ethanol and water bottles in each cage was alternated daily to 
avoid the development of a bottle position preference.  Mouse body weights were 
measured every other day throughout the drinking periods of the experiment at 
approximately two hours into the dark cycle.   
 
Chronic intermittent ethanol exposure 
Chronic intermittent ethanol vapor exposure models have been previously shown 
to lead to ethanol dependence as characterized by an escalation in volitional ethanol 
intake and the presence of ethanol withdrawal seizures (Becker and Hale, 1993; Becker 
and Lopez, 2004; Lopez and Becker, 2005).  A variation of this basic procedure was 
employed in the current studies.  The ethanol vapor set up consisted of air-tight 
biocontainment mouse cages (Allentown Inc., Allentown, NJ) that resembled typical 
polycarbonate mouse cages with the following exceptions – the tops for each cage were 
specifically designed to form an air-tight seal, as well as, inlet and outlet ports built in to 
the cage tops and bottoms, respectively.  Three hundred milliliters of 95% ethanol in a 
side arm flask were volatilized by bubbling with air at a flow rate between 200-400 
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mLs/minute.  The resulting ethanol vapor was combined with air at a flow rate of 3.75 
L/minute (for a total flow rate of ~4L/minute).  The diluted ethanol vapor was channeled 
into the ethanol vapor cages containing up to four mice.  The 95% ethanol in the flask 
was refilled daily to 300 mLs.  The ethanol flow rate was adjusted daily to yield 
empirically determined blood ethanol concentrations (BECs) between 175-225 mg/dL 
(~38-48 mM).  Air control cages were run in parallel to the ethanol vapor cages except 
the ethanol vapor stream was not combined with the normal air stream.   
Following the final day of baseline ethanol consumption, mice were divided into 
chronic intermittent ethanol (CIE) and control (Air) groups with matched levels of 
baseline ethanol consumption.  Immediately before beginning the ethanol vapor or air 
control exposure (at 1700 hours) mice received an ip injection with either an 
ethanol/pyrazole/PBS or a pyrazole/PBS solution, for CIE or Air control mice, 
respectively.  The ethanol/pyrazole/PBS solution contained 20% ethanol (v/v) and 1 mM 
pyrazole in sterile PBS and was intended to act as a loading ethanol dose (1.5 g/kg) to 
reach the target blood ethanol concentration.  The pyrazole was included to help maintain 
steady BECs on account of its inhibition of alcohol dehydrogenase.  The pyrazole/PBS 
solution was identical with the omission of the ethanol.  After sixteen hours of ethanol or 
air vapor exposure (0900 hours), mice were removed from their respective chambers, 
lightly anesthetized with isoflurane, and tail blood samples collected for BEC 
determination (described below).    The ethanol exposure procedure was repeated for four 
consecutive days and followed by a three day withdrawal period at which time limited 
access two bottle choice ethanol consumption was again measured for five days.  The day 
after this five day drinking period, mice underwent a second bout of chronic intermittent 
ethanol or air vapor exposure as before.   
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Gas chromatography 
Tail blood samples were collected for every mouse immediately after the end of 
each ethanol vapor exposure period and assayed to determine the blood ethanol 
concentration.  Two, ten microliter samples of whole blood were collected and added to 
10 mL vials containing 90 µLs of saturated saline (~5.5 M) and sealed with a septum 
until samples from all of the mice could be obtained.   
Once all of the samples for the day had been collected, they were prepared for gas 
chromatography with a Bruker 430-GC (Bruker Corporation, Fremont, CA) equipped 
with a flame ionization detector and Combi PAL autosampler.  Briefly, the samples were 
loaded onto the autosampler and the program was started.  Each sample was warmed to 
65°C for three minutes before the solid-phase microextraction fiber (SPME; 75 µm 
CAR/PDMS, fused silica; Supelco, Bellefonte, PA) absorbed the ethanol vapor for three 
minutes.  The SPME fiber then desorbed the sample into the GC injection port for one 
minute at 220°C.  Helium, at a flow rate of 8.5 mL/minute was used as the carrier gas and 
a capillary column (30 m x 0.53 mm x 1 µm film thickness; Agilent Technologies, Santa 
Clara, CA) was used for separation.   
The resultant chromatograms were analyzed using CompassCDS Workstation 
software (Bruker Corporation, Fremont, CA).  Known ethanol standards were included in 
every GC run and the peak heights for ethanol (~1.9-2.1 minutes retention time) were 
used to construct a standard curve.  The peak heights of all samples were then compared 
against their respective standard curve and used to determine BEC.  If necessary, ethanol 
vapor flow levels were adjusted to ensure that BEC remained in the target range of 175-
225 mg/dL (~38-48 mM) for each experimental mouse.   
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Electrophysiology 
Whole-cell voltage clamp recordings were obtained on visually identified central 
amygdala neurons using an Olympus BX-50WI microscope with IR-DIC optics (Leeds 
Instruments, Irving, TX) and a Dage MTI VE 1000 video camera and controller (Dage-
MTI, Michigan City, IN) mounted on a vibration isolation table.  Recording electrodes 
were pulled from borosilicate glass capillary tubes with a filament (WPI Inc., Sarasota, 
FL) using a Brown-Flaming model P-88 electrode puller (Sutter Instruments, San Rafael, 
CA).  Only electrodes with resistances between 4-7 MΩ were used for experiments.  The 
recording electrodes for all experiments were filled with an intracellular solution 
containing (in mM):  120 CsMeSO4, 15 CsCl, 8 NaCl, 10 HEPES, 0.2 EGTA, 10 
TEA•Cl-, 4 ATP•Mg2+, 0.3 ATP•Na+, 0.1 Spermine, and 5 QX-314•Cl- (Alomone Labs, 
Jerusalem, Israel), osmolarity 280-290 mOsm, pH 7.3 with CsOH.  Excitatory post 
synaptic currents (EPSCs) were electrically evoked with a stainless steel bipolar 
stimulating electrode (FHC, Inc., Bowdoin, ME) and an Isostim A320 stimulator (WPI 
Inc., Sarasota, FL).  Stimulation intensities ranged from 10-75 µA.  Data were acquired 
with either a PC-501A (Warner Instrument Co., Hamden, CT) or a PC-ONE (Dagan 
Corporation, Minneapolis, MN) amplifier, filtered at 2 kHz, and digitized at 10 kHz with 
a Digidata 1200 Series digitizer and interface board using pClamp 8.2 (Axon Instruments, 
Foster City, CA).  Access resistance was monitored throughout all experiments by 
application of a 100 ms, -10 mV step and cells with changes >20% were excluded from 
the study.   
For the experiments examining the effects of CART peptide (55-102 fragment; 
American Peptide Company, Sunnyvale, CA) on central amygdala neurons, 4-5 week 
old, male C57BL6J mice were anesthetized with isoflurane and rapidly decapitated.  The 
brains were rapidly extracted and placed in ice-cold (4°C) cutting artificial cerebrospinal 
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fluid (ACSF) that had been bubbled with 95% O2/5% CO2 and contained (in mM):  210 
sucrose, 26.2 NaHCO3, 1 NaH2PO4, 2.5 KCl, 11 dextrose, 2.5 CaCl2, and 6 MgSO4 for 
three to five minutes.  The brain was then mounted onto the cutting stage of a VT1000S 
vibratome (Leica, Nussloch, Germany) with a cyanoacrylate adhesive and 230-250 µm 
thick coronal slices containing the central amygdala (approximately -1.3 to -1.9 Bregma) 
were prepared in the same cutting ACSF used before.  Immediately after being cut, the 
slices were bisected along the midline and incubated at 32°C in a recovery ACSF 
continuously bubbled with 95% O2/5% CO2 and containing (in mM):  124 NaCl, 26 
NaHCO3, 10 dextrose, 4.4 KCl, 1 NaH2PO4, 1.8 CaCl2, and 2.4 MgSO4.  The slices were 
incubated for at least one hour before electrophysiological recordings were performed.   
For electrophysiological recording, slices were transferred to a recording chamber 
and perfused at a flow rate of ~2 mLs/minute with room temperature (21-23°C) recording 
ACSF continuously bubbled with 95% O2/5% CO2 and containing (in mM):  124 NaCl, 
26 NaHCO3, 10 dextrose, 4.4 KCl, 1 NaH2PO4, 2 CaCl2, and 1.2 MgSO4.  Picrotoxin (50 
µM) was added to the recording solution for all experiments to inhibit any GABAA 
receptor-mediated inhibitory synaptic currents.  Miniature EPSCs (mEPSCs) were 
recorded in the presence of 500 nM tetrodotoxin (TTX; Alomone Labs, Jerusalem, Israel) 
to block any action potential-mediated events; this concentration eliminated all 
electrically evoked EPSCs in pilot experiments (data not shown).  For AMPA/NMDA 
ratio determinations, the recording ACSF MgSO4 concentration was reduced to 0.5 mM 
to facilitate NMDA receptor-mediated responses.  In every neuron, after achieving a 
whole-cell configuration (with neurons clamped at -80 mV), a five minute 
wait/equilibration period was taken to allow the intracellular solution to equilibrate with 
the cell cytoplasm.  During this wait period, spontaneous EPSC activity was monitored.  
Three neurons displayed no spontaneous activity during this period and those recordings 
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were terminated.  For recordings involving electrically evoked EPSCs (eEPSCs), the 
stimulation intensity was determined immediately following the equilibration period to 
yield consistent sub-maximal currents. 
For mEPSC recordings, recording ACSF containing TTX was washed on after the 
equilibration period for at least five minutes before proceeding with the recording.  Five 
minutes (30 sweeps, 10 seconds/sweep) of mEPSC activity was then recorded to 
determine the baseline activity level.  Then CART peptide (500 nM) was bath applied 
with the recording ACSF for a fifteen minute period with mEPSC activity recorded for 
the last five minutes of the fifteen minute period.  After a ten minute wash out period, 
miniature activity was recorded for an additional five minutes.  For mEPSC recordings, 
quantal events were analyzed using the event detection module in Clampfit 10.3 (Axon 
Instruments, Foster City, CA).  Briefly, a template mEPSC was constructed by averaging 
200 quantal events and then using this template to scan sweeps for spontaneous quantal 
events.  These events were manually inspected to ensure the template was suitable and 
that no false events were detected.  Quantal events with a peak amplitude of less than five 
picoamps were omitted from the analysis because they could not be reliably differentiated 
from background noise levels. 
For the determination of AMPA/NMDA ratios, eEPSCs were collected at -80 mV 
and at +40 mV in the presence of reduced MgSO4.  Evoked EPSCs collected at -80 mV 
were insensitive to application of the NMDA receptor antagonist CPP (20 µM; data not 
shown) in pilot experiments thus confirming that these eEPSCs were strictly AMPA 
receptor-mediated.  EPSCs collected at +40 mV were compound AMPA and NMDA 
receptor-mediated currents.  Application of a NMDA receptor antagonist, DL-AP5 (100 
µM; Tocris Bioscience, Minneapolis, MN), was used to pharmacologically isolate the 
AMPA receptor-mediated portion of the compound current collected at +40 mV and to 
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determine the time at which the AMPA receptor-mediated portion of the current was 
attenuated.  This time (65 ms after the stimulus artifact) was then used to determine the 
peak of the NMDA receptor-mediated currents for AMPA/NMDA ratio calculations.  
Twelve, one minute trials consisting of an eEPSC at -80 mV followed by a +40 mV 
eEPSC ten seconds later were conducted.  The AMPA and NMDA peaks were analyzed, 
averaged, and compiled to yield the AMPA/NMDA ratio.  This procedure was carried out 
before the application of CART peptide (500 nM), after ten minutes in CART peptide, 
and after a 10 minute wash out period. 
For mice from the chronic intermittent ethanol vapor exposure study, spontaneous 
EPSCs (sEPSCs) were collected in a manner similar to mEPSCs except that no TTX was 
present in the recording solution and the MgSO4 concentration was reduced to 0.5 mM to 
allow for determination of AMPA/NMDA ratios following collection of the sEPSC 
activity.  The AMPA receptor antagonist, DNQX (20 µM; Tocris Bioscience, 
Minneapolis, MN), was used periodically after recordings were gathered to confirm that  
-80 mV EPSCs were AMPA receptor-mediated.  Tetrodotoxin was excluded from these 
studies because it was found to have no significant effects on sEPSCs (average peak 
amplitude and frequency) in central amygdala neurons (data not shown).  As before, after 
a five minute equilibration period, sEPSC activity was collected for a five minute period.  
A separate template was constructed, using the same process as for the mEPSC template, 
for the analysis of sEPSCs from mice in the CIE experiment.  Following the collection of 
sEPSC activity, the stimulation intensity was established and the AMPA/NMDA ratio 
was determined as before.   
Paired pulse ratios were determined in mice from the CIE experiment to 
determine if any presynaptic neuroadaptations resulted from CIE treatment.  After the 
equilibration period, the stimulation intensity was determined as before.  Then the ratios 
 70 
were calculated by recording 15 sweeps consisting of two paired eEPSCs at -80 mV with 
a 25, 50, or 250 millisecond interstimulus interval for each interstimulus interval tested.  
Each sweep was separated by a 30 second period of time.  For analysis of the paired pulse 
ratios, the peak amplitudes of both eEPSCs were calculated in Clampfit 10.3 (Axon 
Instruments, Foster City, CA) and exported to a spreadsheet for determination of the ratio 
of the second eEPSC to first eEPSC. 
Except where noted, all chemicals were obtained from Sigma Aldrich (St. Louis, 
MO).  
 
Statistics 
All data are reported as the mean ± the standard error of the mean.  All data were 
compiled and organized in Microsoft Excel spreadsheets and exported to R 2.15.0 
(www.R-project.org) or IBM SPSS Statistics 21 (IBM, Armonk, NY) for analysis; 
specifically, MANOVAs were completed in SPSS and all other statistical tests were 
conducted in R. 
Single-factor, repeated measures ANOVAs with Bonferroni post hocs were used 
to examine differences in mEPSC frequency, mEPSC amplitude, and AMPA/NMDA 
ratios in the acute CART peptide electrophysiological experiments.  For the light/dark 
box validation experiment, a single-factor (restraint stress/non-stress) Multivariate 
ANOVA (MANOVA) was used for the behavioral experiments and an unpaired t-test 
was used to examine for differences in the corticosterone ELISA in this experiment.  For 
the examination of basal anxiety-like behaviors between genotypes, a single factor 
MANOVA was used.  For the experiment examining stress responsivity between 
genotypes, a two-factor (restraint stress/non-stress and genotype) MANOVA was used 
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for the behavioral light/dark box data and a two-factor ANOVA was used to determine 
any statistical differences in the corticosterone ELISA data.  For the ethanol consumption 
data in the CIE experiment, a two-factor (CIE treatment and genotype) repeated measures 
(baseline and post-CIE) ANOVA was used.  For the light/dark box behavioral data and 
paired pulse ratio data in the CIE experiment, two-factor MANOVAs were used.  Two-
factor (CIE treatment and genotype) ANOVAs were used to examine the corticosterone 
ELISA data, sEPSC peak amplitudes, sEPSC frequencies, and AMPA/NMDA ratios.   
 
 
RESULTS 
Effects of acute CART peptide on mEPSCs and AMPA/NMDA ratios 
Acute application of 500 nM CART peptide did not have any significant effects 
on mEPSCs.  Neither the average event peak amplitude nor the average event frequency 
was altered in the presence of CART peptide or after a ten minute washout period (Figure 
6).  The same 500 nM dose of CART peptide did result in a significant decrease in the 
AMPA/NMDA ratio (F(1,5)=9.024, p<0.05; figure 7).  Given that CART had no effect 
on mEPSC amplitude and that the mEPSCs recorded were AMPA receptor-mediated (i.e. 
holding potential was -80 mV and the currents were DNQX-sensitive; data not shown) 
we can presume that the CART effect on AMPA/NMDA ratios is driven by a CART 
enhancement of NMDA receptor-mediated currents and not any effects of CART on 
AMPA receptor-mediated currents. 
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Figure 6.  CART peptide (500 nM) had no effect on mEPSC peak amplitude or frequency 
 
 
Neither the average event frequency nor the average event peak amplitude was altered in 
the presence of CART peptide.  Washout of CART peptide also had no effect on 
mEPSCs.  (A) Sample mEPSC activity recorded under baseline conditions, in the 
presence of CART, and after a washout period.  (B) A bar graph representing the average 
mEPSC frequencies in all three conditions.  (C) A bar graph representing the average 
mEPSC peak amplitude in all three conditions.  n=10 cells from 8 mice.   
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Figure 7.  CART peptide (500 nM) reduced AMPA/NMDA ratios in central amygdala 
neurons 
 
 
Application of CART peptide reduced AMPA/NMDA ratios of central amygdala 
neurons.  (A) Sample traces of the AMPA receptor-mediated currents collected at -80 mV 
(in red) and the compound AMPA & NMDA receptor-mediated currents collected at +40 
mV (in black) under baseline (pre CART) and CART peptide conditions.  (B) A bar 
graph representing the average AMPA/NMDA ratio under each condition.  The average 
AMPA/NMDA ratio was significantly reduced in the presence of 500 nM CART peptide. 
n=6 cells from 6 mice.  *, p<0.05 
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Validation of the light/dark box for assessment of anxiety-like behaviors 
Before beginning any long term studies with an untested behavioral assay (at least 
in our lab), we decided to perform a positive control experiment.  We briefly exposed 
mice to an empty, novel cage or an acute mild restraint stress and then assessed anxiety-
like behaviors in the light/dark box assay.   
The latency time to the first transition into the dark compartment was compared 
between the two groups and a trend towards a decreased latency time was found in 
stressed mice (F(1,13)=1.829, p<0.1, Figure 8A).  Given that mice begin the assay in the 
light compartment, it is believed that a lower latency time may reflect an increase in 
anxiety.  The number of transitions between the light and dark compartments was 
compared between the two treatment groups to determine if there was any difference in 
general locomotor or exploratory activity.  The average number of transitions did not 
differ between the two groups (Figure 8B).  The total amount of time spent in the light 
and dark compartments was compared between the treatment groups.  Acutely restrained 
mice displayed significantly less time in the light compartment than their non-stressed 
counterparts (F(1,13)=13.4, p<0.01; Figure 8C).  This decrease in time spent in the light 
compartment was accompanied by a significant increase in time spent in the dark 
compartment of the apparatus (F(1,13)=13.4, p<0.01; Figure 8C).  Given the natural 
aversion of rodents to brightly lit, open areas, we can infer that the decrease in time spent 
in the light compartment (and concomitant increase in time spent in the dark 
compartment) in stressed mice reflects an increased anxiety state relative to control mice.  
The number of fecal boli deposited in the DecapiCone™ and the light/dark box were 
counted.  Stressed mice deposited significantly more fecal boli than their non-stressed 
counterparts (F(1,13)=28.5, p<0.001; Figure 8D).  Exploratory rearing behaviors were 
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also tabulated and found to be significantly decreased in stressed mice (F(1,13)=9.5, 
p<0.01, Figure 8E).   
Immediately following the light/dark box assay trunk blood samples were 
collected, the plasma isolated, and stored until assaying for corticosterone content.  A 
corticosterone ELISA of the plasma samples determined that acutely restrained mice had 
a significantly higher plasma corticosterone content than their non-stressed counterparts 
(t(16)=-4.7; p<0.001; Figure 9).   
Taken together, the behavioral and physiological measures (corticosterone 
content) support the conclusion that mice with an increased anxiety state will display 
increases in anxiety-like behaviors in the light/dark box assay and further, they will have 
greater plasma corticosterone levels than mice with a decreased anxiety state. 
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Figure 8.  An acute restraint stress exposure increased anxiety-like behaviors in the 
light/dark box assay 
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Acutely restrained mice displayed increased anxiety-like behaviors in the light/dark box 
assay.  Bar graph representations of the average latency time of the first transition into the 
dark compartment of the box (A), the average number of transitions between the light and 
dark compartments (B), the average amounts of time spent in the light and dark 
compartments (C), the average number of fecal boli deposited (D), and the average 
number of exploratory rearing behaviors (E).  n=8 and 7 for non-stressed and restraint 
stressed groups, respectively.  ‡, p<0.1; **, p<0.01; ***, p<0.001 compared to non-
stressed controls   
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Figure 9.  Plasma corticosterone was increased in acutely restrained mice 
 
 
Acutely restrained mice had increased plasma corticosterone content relative to their non-
stressed counterparts.  n=9 per treatment group.  ***, p<0.001 
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Comparison of basal anxiety-like behaviors between CART KO and WT mice 
Given that these studies would be the first to examine anxiety behaviors in CART 
KO mice, we first sought to compare baseline anxiety levels in CART KO and WT mice 
using the light/dark box assay.  We found no significant genotype differences in any of 
the light/dark box parameters examined (Table 1).  These findings suggest that there are 
no unforeseen compensatory effects in the (global) CART knockout mice under basal 
conditions. 
 
Table 1. Basal anxiety-like behaviors do not differ between CART KO and WT mice 
 
 
Values are mean ± SEM.  No significant differences were detected across any of the 
parameters examined.  n=6 for CART knockout mice and n=7 for CART wild type mice 
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Anxiety/stress responsivity in CART KO and WT mice 
Given the presence of CART at every level of the HPA axis and its putative role 
in the stress response, we performed an additional experiment to examine anxiety/stress 
responsivity in CART KO and WT mice.  To that end, mice of both genotypes were 
exposed to an acute restraint stress or a clean novel cage before being tested in the 
light/dark box assay and having trunk bloods collected for later determination of 
corticosterone content. 
We found a significant main effect of restraint stress treatment on the latency to 
first transition (F(1,28)=4.24, p<0.05; Figure 10A), the number of transitions to the dark 
compartment (F(1,28)=16.24, p<0.001; Figure 10B), the amount of time spent in the light 
compartment (F(1,28)=23.63, p<0.001; Figure 10C), the amount of time spent in the dark 
compartment (F(1,28)=23.8, p<0.001; Figure 10D), the number of fecal boli 
(F(1,28)=19.35, p<0.001; Figure 10E), and the number of rears (F(1,28)=32.56, p<0.001; 
Figure 10F).  There was a significant effect of genotype on the latency to the first 
transition (F(1,28)=7.04, p<0.05) and a trend towards a genotype effect on the number of 
transitions to the dark compartment (F1,28)=3.75, p<0.1).  There was also a significant 
treatment by genotype interaction effect (F=(1,28)=5.05; p<0.05) on the number of 
transitions and a trend towards a significant treatment by genotype effect (F1,28)=3.49; 
p<0.1) on the latency to the first transition.  Taken together, these results suggest that 
acutely stressed mice of both genotypes displayed an increase in anxiety-like behaviors 
relative to their respective non-stressed counterpart control mice. 
After assaying the plasma corticosterone content of each mouse, we found a 
significant main effect of restraint stress treatment (F(1,33)=57.56, p<0.001) such that 
corticosterone was increased in restraint stress treated mice.  We also found a significant 
main effect of genotype (F(1,33)=5.25, p<0.05) and a significant treatment by genotype 
 81 
interaction effect (F(1,33)=13.44, p<0.01) such that CART KO mice seemed to have a 
potentiated corticosterone response compared to their WT counterparts (Figure 11). 
Taken together, the behavioral observations show no evidence for a significant 
difference between CART KO and WT mice in an acute restraint stress test.  However, 
the corticosterone data are not in accord with the behavioral data for CART KO mice.  
That is to say, the behavioral data do not reflect the potentiated corticosterone response 
observed in CART KO mice relative to WT mice and could represent a limitation of the 
behavioral assay.  It is also possible that HPA axis function is dysregulated in CART KO 
mice such that changes in anxiety states may not be accurately reflected or accompanied 
by changes in corticosterone content.  
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Figure 10.  Acute restraint stress increased anxiety-like behaviors in CART KO and WT 
mice 
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Acutely restrained mice of both genotypes exhibited increases in anxiety like behaviors.  
Bar graph representations of the average latency time of the first transition into the dark 
compartment of the box (A), the average number of transitions between the light and dark 
compartments (B), the average amounts of time spent in the light and dark compartments 
(C), the average number of fecal boli deposited (D), and the average number of 
exploratory rearing behaviors (E).  There was a main effect of treatment (non-stressed 
versus stressed) in all of the parameters examined (denoted by asterisks; *, p<0.05; ***, 
p<0.001).  There was a significant main effect of genotype (p<0.05) on the latency to the 
first transition and a trend towards significance (p<0.1) for a treatment by genotype 
interaction (denoted by ‡).  There was a trend towards a main effect of genotype (p<0.1) 
and a significant treatment by genotype interaction effect (p<0.05) on the number of 
transitions to the dark compartment (denoted by +).  n=8-9 per group 
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Figure 11.  CART KO and WT mice had increased plasma corticosterone in response to 
an acute restraint stress 
 
 
Corticosterone was increased in acutely restrained mice of both genotypes.  CART KO 
mice displayed a potentiated corticosterone response relative the CART WT mice in 
response to the acute restraint stress session.   n=8-10 per group.  ***, p<0.001; ‡ denotes 
a significant treatment by genotype interaction (p<0.01) and a significant main effect of 
genotype (p<0.05).   
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Chronic intermittent ethanol vapor exposure increased ethanol consumption 
In order for the CIE procedure to be effective, the blood ethanol content must be 
consistently between 175-225 mg/dL or 38-48 mM.  The average BEC for all mice in the 
CIE groups was 42.4±2.2 mM (n=36), well within the necessary levels to achieve a CIE 
effect on ethanol consumption.  There were no differences in BEC between genotypes or 
across CIE cycles (Figure 12).  The average BEC for mice in the Air control group was 
always well below the limit of detection of our standard curve (~2.5 mM) and could not 
be distinguished from background noise levels on chromatographs.   
Mice in all of the treatment groups had an increase in their average ethanol 
consumption (Pre-CIE versus Post-CIE, F(1,39)=8.46, p<0.01); however, there was a 
main effect of treatment (Air versus CIE, F(1,39)=6.96, p<0.05) such that only CIE-
treated mice (of both genotypes) had significant escalations in ethanol consumption.  
There were trends towards a genotype effect (F(1,39)=3.95, p<0.1) such that CART KO 
mice may consume less ethanol that WT mice.  There was also a trend for a treatment by 
genotype interaction effect (F(1,39)=3.58, p<0.1) such that CART KO mice in the CIE 
treatment group, specifically, may consume less ethanol than CIE treated WT mice.  The 
average daily ethanol consumption levels for each group are shown in figure 13A and the 
average ethanol consumption over the measured, five day, pre- and post-CIE drinking 
periods is summarized in figure 13B. 
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Figure 12.  Blood ethanol concentrations were consistent during both CIE cycles 
 
 
Blood ethanol concentrations did not differ between genotypes or CIE cycles.  Air control 
mice had no detectable blood ethanol concentrations.  n=8-14 per group 
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Figure 13.  Chronic intermittent ethanol increased ethanol consumption 
 
 
Mice that underwent chronic intermittent ethanol treatment of both sexes increased 
ethanol intake.  There was a trend towards CART KO mice consuming less ethanol than 
their WT counterparts.  (A) Ethanol consumption broken down by daily consumption and 
(B) bar graph representation of the average total ethanol consumption before and after 
CIE treatment. n=8-14 per group. *, p<0.05 relative to pre-CIE consumption; ‡, p<0.1 
relative to WT CIE 
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Withdrawal from chronic intermittent ethanol reduces exploratory behaviors in the 
light/dark assay 
Chronic intermittent ethanol treatment resulted in significant decreases in 
exploratory behaviors in mice of both genotypes.  The number of transitions between 
compartments (Figure 14B) and the number of exploratory rears (Figure 14F) were 
significantly reduced following CIE treatment (F(1,33)=52.01, p<0.001 & F(1,33)=29.83, 
p<0.001, respectively, for number of transitions and rears).  There was also a significant 
increase in the latency to the first transition (Figure 14A) in CIE-treated mice 
(F(1,33)=5.9, p<0.05), however, this result may just be a reflection of the overall 
decrease in the number of transitions between compartments.  There was a significant 
genotype by treatment interaction (F(1,33)=4.64, p<0.05) such that WT mice in the CIE 
treatment group had fewer fecal boli than the other treatment groups (Figure 14E).  There 
were no significant genotype, treatment, or interaction effects on the amount of time mice 
spent in the light and dark compartments of each box (Figure 14C & D). 
Withdrawal from two bouts of chronic intermittent ethanol treatment had 
significant inhibitory main effects on exploratory behaviors in both genotypes.  The 
number of transitions between compartments was decreased in CIE-treated mice 
(F(1,29)=20.96, p<0.001; Figure 15B) relative to Air-treated mice.  Similarly, the rearing 
exploratory behaviors were also significantly decreased (F(1,29)=23.08, p<0.001; Figure 
15F) in CIE-treated mice of both genotypes when compared to the Air-treated mice.  
There was no significant effect of CIE on the total amount of time spent in the light or 
dark compartments; however, there was a significant effect of genotype such that CART 
KO mice spent a greater amount of time in the light compartment (F(1,29=7.02, p<0.05; 
Figure 15C) than WT mice in both the Air and CIE treatment groups.  Accordingly, 
CART KO mice spent less time in the dark compartment (F(1,29)=7.02, p<0.05; Figure 
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15D) than WT mice in both treatment groups.  There was also a trend towards a genotype 
effect on the latency time to the first transition such that CART KO mice in both 
treatment groups had a greater latency time (F(1,29)=3.27, p<0.1; Figure 15A) than WT 
mice.  There were no significant difference in the number of fecal boli between 
genotypes or treatment groups (Figure 15E).   
Overall, it appears that one or two bouts of CIE treatment and acute withdrawal 
result in a modest increases in anxiety-like behaviors.  Specifically, exploratory behaviors 
were significantly inhibited during withdrawal while the overall amount of time spent in 
the light and dark compartments was unaffected by CIE treatment.  Interestingly, a 
genotype difference in anxiety-like behaviors arose during the course of the experiment 
such that CART KO mice in both treatment groups spent significantly more time in the 
light compartment than WT mice following the second CIE bout. 
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Figure 14.  Withdrawal from one bout of chronic intermittent ethanol reduces exploratory 
behaviors in the light/dark box assay 
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Acute withdrawal from chronic intermittent ethanol decreases exploratory behaviors in 
the light/dark box assay. Bar graph representations of the average latency time of the first 
transition into the dark compartment of the box (A), the average number of transitions 
between the light and dark compartments (B), the average amounts of time spent in the 
light and dark compartments (C), the average number of fecal boli deposited (D), and the 
average number of exploratory rearing behaviors (E).  n=8-11 mice per group.  *, p<0.05; 
***, p<0.001  
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Figure 15.  Light/Dark box behaviors during the second withdrawal from chronic 
intermittent ethanol 
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Withdrawal from two bouts of chronic intermittent ethanol significantly decreased the 
number of transitions between compartments and exploratory rearing behavior in mice of 
both genotypes.  Bar graph representations of the average latency time of the first 
transition into the dark compartment of the box (A), the average number of transitions 
between the light and dark compartments (B), the average amounts of time spent in the 
light and dark compartments (C), the average number of fecal boli deposited (D), and the 
average number of exploratory rearing behaviors (E).  n=6-10 mice per group.  ‡, p<0.1 
compared to WT mice; **, p<0.01 compared to WT mice; ***, p<0.001 compared to Air 
treatment.   
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Corticosterone is increased during withdrawal from chronic intermittent ethanol  
Plasma corticosterone levels were significantly increased in mice of both 
genotypes during withdrawal from chronic intermittent ethanol (F(1,35)=35.45, p<0.001; 
Figure 16).  Interestingly, there was no effect of genotype on plasma corticosterone levels 
in either treatment.  There was also no significant genotype by treatment interaction 
effect.  These results match the behavioral observations in that they demonstrate an 
increase in stress in CIE-treated mice; however, they do not reflect the genotype effect 
observed for CART KO mice. 
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Figure 16.  Plasma corticosterone was increased during withdrawal from chronic 
intermittent ethanol vapor exposure 
 
 
Withdrawal from chronic intermittent ethanol treatment significantly increased plasma 
corticosterone levels in CART KO and WT mice.  n=9-12 per group.  ***, p<0.001 
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Chronic intermittent ethanol increases sEPSC amplitudes in mice of both genotypes 
Central amygdala sEPSC activity was measured in mice from all treatment groups 
(representative traces in Figure 17A).  We found no significant main effects of treatment, 
genotype, or a treatment by genotype interaction on the frequency of sEPSCs (Figure 
17B); however, there was a main effect of chronic intermittent ethanol treatment on 
sEPSC amplitude (F(1,26)=13.42, p<0.01; Figure 17C) such that CIE-treated mice had a 
greater average sEPSC amplitude than Air treatment controls in both genotypes.  There 
was no significant effect of genotype or a treatment by genotype effect on sEPSC 
amplitude.   
The observed increase in sEPSC amplitude in CIE-treated mice of both genotypes 
is indicative of a post synaptic modification in glutamatergic neurotransmission.  
Furthermore, since sEPSCs recorded at -80 mV are completely inhibited by DNQX, an 
AMPA receptor antagonist, we may presume that the post synaptic modification involves 
AMPA receptors.  This neuroadaptation could be involved in mediating the observed 
increases in ethanol consumption following CIE exposure or in modulating the anxiety-
like behaviors observed during withdrawal from CIE.   
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Figure 17.  Chronic intermittent ethanol increases sEPSC amplitude 
 
 
(A) Sample traces of spontaneous EPSC activity from all four treatment conditions.  (B) 
Bar graph representation of sEPSC frequencies.  There were no differences in sEPSC 
frequency between genotype or treatment groups.  (C) Bar graph representation of sEPSC 
amplitudes.  Chronic intermittent ethanol treatment significantly increased sEPSC 
amplitudes in both CART KO and WT mice.  n=6-10 cells per group from 3-8 mice per 
group.  **, p<0.01 
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Chronic intermittent ethanol did not affect AMPA/NMDA ratios 
In addition to monitoring sEPSC activity, we also assessed the AMPA/NMDA 
ratio of central amygdala neurons in mice from each treatment group.  We found that 
there were no main effects of genotype or CIE treatment on AMPA/NMDA ratios in any 
of the treatment groups.  We also found that there was no significant genotype by 
treatment interaction effect on the AMPA/NMDA ratios (Figure 22).   
 
 
Figure 18.  AMPA/NMDA Ratios do not differ between treatment groups 
 
 
Bar graph representation of average AMPA/NMDA ratios from all treatment groups.  
There were no changes in the ratios in response to CIE treatment or genotype.  n=7-12 
cells from 4-8 mice 
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Chronic intermittent ethanol decreases presynaptic release probability 
The final electrophysiological parameter assessed in this study was the paired 
pulse ratios of eEPSCs at 25, 50, and 250 millisecond interstimulus intervals (Figure 19).  
We found that there were no main effects of CIE treatment or genotype at any of the 
interstimulus intervals tested; however, chronic intermittent ethanol exposure resulted in 
a significant treatment by genotype interaction effect such that the paired pulse ratio was 
increased at the 25 millisecond interstimulus interval for WT mice (F(1,24)=5.99, 
p<0.05).  There was also a trend for a significant treatment by genotype interaction for 
the 250 millisecond interstimulus interval for WT mice (F(1,24)=2.72, p<0.1).  The 
observed increase in paired pulse ratio in this study may represent an additional 
neuroadaptation that contributes to the observed increase in anxiety-like behaviors during 
withdrawal from CIE.  It is noteworthy, however, that the increase in paired pulse ratio 
was unique to WT mice, whereas, the increase in behavioral anxiety measures may not 
be.   
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Figure 19.  Chronic intermittent ethanol increased paired pulse ratios 
 
 
Chronic intermittent ethanol treatment increased paired pulse ratios in WT mice at the 25 
millisecond interval, suggesting decreased presynaptic release probability.  (A) Sample 
traces of paired pulse experiments at the 25 ms interstimulus interval for each genotype 
and CIE treatment.  (B) Bar graph representation of paired pulse ratio data.  n=4-10 cells 
per group from 3-7 mice.  *, p<0.05 & ‡, p<0.1 relative to all other treatment groups 
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Table 2. Summary of results 
Experiment Result Significance Figure/Reference 
CART peptide effects on mEPSCs and AMPA/NMDA ratio 
mEPSC frequency  No effect None 6A 
mEPSC amplitude No effect None 6B 
AMPA/NMDA Ratio  ↓ p<0.05 7 
Acute restraint stress in CART KO and WT mice 
Latency to first transition 
          Stress effect 
 
↓ 
 
p<0.05 
 
10A 
Transitions between compartments 
          Stress effect 
          Genotype by stress effect 
 
↓ 
↑ in NS WT 
 
p<0.001 
p<0.05 
 
10B 
 
Time spent in light 
          Stress effect 
 
↓ 
 
p<0.001 
 
10C 
Time spent in dark 
          Stress effect 
 
↑ 
 
p<0.001 
 
10D 
Fecal Boli 
          Stress effect 
 
↑ 
 
p<0.001 
 
10E 
Rears 
          Stress effect 
 
↓ 
 
p<0.001 
 
10F 
Corticosterone 
          Stress effect 
          Genotype effect 
          Genotype by stress effect 
 
↑ 
↑ in KO 
↑ in RS KO 
 
p<0.001 
p<0.05 
p<0.01 
 
11 
Ethanol consumption  
          Pre-vs-post CIE 
          Genotype effect 
          Treatment effect 
          Genotype by treatment effect 
↑ 
↑ in WT 
↑ in CIE 
↓ in CIE KO 
p<0.01 
p<0.1 
p<0.05 
p<0.1 
13 
Anxiety-like behaviors following one bout of CIE 
Latency to first transition 
          CIE effect 
 
↑ 
 
p<0.05 
 
14A 
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Table 2, continued    
Transitions between compartments 
          CIE effect  
 
↓ 
 
p<0.001 
 
14B 
Time spent in light           No differences  14C 
Time spent in dark No differences  14D 
Fecal Boli 
          Stress effect 
 
↓ in CIE WT 
 
P<0.05 
 
14E 
Rears 
          CIE effect 
 
↓ 
 
p<0.001 
 
14F 
Anxiety-like behaviors and corticosterone following two bouts of CIE 
Latency to first transition 
          Genotype effect 
 
↑ 
 
p<0.1 
 
15A 
Transitions between compartments 
          CIE effect  
 
↓ 
 
p<0.001 
 
15B 
Time spent in light  
          Genotype effect          
 
↑ 
 
p<0.01 
 
15C 
Time spent in dark 
          Genotype effect  
 
↓ 
 
p<0.01 
 
15D 
Fecal Boli        No differences  15E 
Rears 
          CIE effect 
 
↓ 
 
p<0.001 
 
15F 
Corticosterone 
          CIE effect         
 
↑ 
 
p<0.001 
 
16 
Electrophysiology measures following two bouts of CIE 
sEPSC Frequency No differences  17B 
sEPSC Amplitude ↑ p<0.01 17C 
AMPA/NMDA Ratio No differences  18 
Paired Pulse Ratio 25 ms 
          Genotype by treatment effect 
 
↑ in CIE WT 
 
p<0.05 
 
19B 
Paired Pulse Ratio 50 ms No differences  19B 
Paired Pulse Ratio 250 ms 
          Genotype by treatment effects 
 
↑ in CIE WT 
 
p<0.1 
 
19B 
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DISCUSSION 
We found that chronic intermittent ethanol treatment produced a number of 
significant behavioral, endocrine, and electrophysiological effects.  We further found that 
some of these effects were attenuated in CART KO mice suggesting a critical role for 
CART peptides in these effects.  
To our knowledge, this study is the first to use CART KO mice to examine 
anxiety- and stress-related behaviors and the first study from our lab to examine anxiety-
related behaviors.   Thus we began by validating our behavioral apparatus – the light/dark 
box – by exposing a group of mice to an acute restraint stress and subsequently 
examining anxiety-like behaviors and plasma corticosterone content.  We found that the 
light/dark box was a suitable assay and that we could reliably detect differences in 
anxiety-like behaviors and corticosterone levels between stressed and non-stressed mice.  
We next chose to compare the stress response between CART KO and WT mice since 
any differences in stress responsivity could have possible implications on the 
interpretation of subsequent studies.  We found that CART KO and WT mice did not 
differ in their behavioral responses to an acute stressor; however, we did find that the 
plasma corticosterone response to an acute stressor was potentiated in CART KO mice 
relative to WT mice.  Given the ubiquitous presence and the complex interactions of 
CART peptides throughout the HPA axis (for review see Koylu et al. (2006) and Rogge 
et al. (2008)), there are a number of possible (neuro)endocrine mechanisms contributing 
to this result.  Determining which of these mechanisms is made difficult not only by the 
presence of CART peptide at every level of the HPA axis, but by the paucity of data 
about stress and anxiety in CART KO mice.  Nonetheless, this novel finding was kept in 
consideration during the interpretation of all subsequent results.  Interestingly, a missense 
mutation in the CART gene (Leu34Phe) was found to result in lower levels of bioactive 
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CART peptide and has been associated with increased anxiety and depression in 
adolescents from an Italian family (Miraglia del Giudice et al., 2006; Yanik et al., 2006).  
Given the potentiated corticosterone response observed in our CART KO mice following 
an acute stressor, it is possible that the Leu34Phe mutation present in humans, which 
significantly reduces bioavailable CART (Dominguez et al., 2004), may recapitulate the 
exaggerated glucocorticoid response to a stressor we observed in our studies.  Following 
this line of reasoning, if every stressor encountered resulted in an aberrant stress 
response, it is possible that the chronic stress conditions (i.e. chronically elevated 
circulating glucocorticoid levels) experienced by people with this mutation contributes to 
or underlies the phenotypic observations of increased anxiety and depression. 
Among the primary effects of CIE treatment, we observed was a significant 
increase in ethanol consumption after a single bout of CIE vapor exposure.  Interestingly, 
there was a statistical trend for a genotype effect such that CART KO mice may consume 
less ethanol than WT mice.  This result would be in accord with our previous data 
demonstrating a significant reduction in ethanol consumption and preference in CART 
KO mice (Salinas et al., 2012); however, the difference in ethanol consumption 
conditions used should be noted.  In our previous results, we employed an unlimited 
access, two bottle choice assay with a number of ethanol concentrations (including the 
15% concentration used in the current study).  The current study (and most CIE models in 
general) utilized a modified drinking-in-the-dark procedure which, by design, are meant 
to escalate ethanol consumption to result in blood ethanol concentrations that correlate 
with behavioral intoxication (Rhodes et al., 2005).  We therefore believe that the 
genotype effect of reduced ethanol consumption in CART KO mice may have been 
masked in this study by the use of a limited access procedure.  There was also a statistical 
trend towards a significant genotype by treatment interaction such that CART KO mice 
 105 
in the CIE group may consume less ethanol than their WT counterparts.  This result may 
reflect a decreased efficacy of chronic intermittent ethanol treatment in CART KO mice 
to increase ethanol consumption and withdrawal anxiety-like behaviors.   
Behaviorally, we found that early withdrawal (~6.5 hours) from a single bout of 
CIE treatment resulted in a significant decrease in exploratory behaviors, suggesting an 
increase in anxiety.  There was also a significant increase in the latency to the first 
transition in CIE-treated mice.  This latter result might imply a decrease in anxiety; 
however, when taken in the context of a reduction in the total number of transitions 
between compartments (which is also a measure of overall locomotor activity), this 
interpretation becomes questionable.  Another possible explanation for this result is that 
the increase in latency time is just a byproduct of the overall reduction in the number of 
transitions between compartments/exploratory activity.  Unexpectedly, we found a 
decrease in the number of fecal boli in CIE WT mice.  Normally, we would interpret this 
as a sign of reduced anxiety, but upon examination of the boli we noticed a marked 
change in texture such that we believe CIE-treated mice may be dehydrated during early 
withdrawal.  Thus, we feel that under these circumstances the number of fecal boli may 
not be a representative measure of an anxious or stressed state. 
Acute withdrawal following two bouts of CIE treatment also resulted in a 
significant decrease in exploratory behaviors (number of transitions between 
compartments and number of exploratory rears), suggesting an increase in anxiety.  
Interestingly, a significant genotype effect on the total amount of time spent in the light 
and dark compartments was unmasked after two CIE cycles such that CART KO mice 
spent more time in the light compartment (with a concomitant decrease in the amount of 
time spent in the dark compartment) suggesting a decrease in anxiety.  This effect was 
present in both Air and CIE treatment conditions to an equal extent.  There was also a 
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statistical trend towards a genotype effect in the latency to the first transition such that 
CART KO mice in both treatment groups had increased latency times.  Given that there 
were no differences in the number of transitions/overall locomotor activity between 
compartments within treatment conditions, the possible increase in latency times in 
CART KO mice may also be interpreted as a decrease in anxiety. 
We then examined the corticosterone content of mice undergoing withdrawal 
from two bouts of CIE immediately following their trial in the light/dark box assay.  We 
found that mice undergoing withdrawal from CIE had nearly twice the amount of 
corticosterone than their respective counterparts in the Air treatment groups, potentially 
supporting the observed behavioral increases in anxiety as measured by decreases in 
exploratory behaviors.  The corticosterone results may not reflect the potential decrease 
in anxiety indicated by the increased amount of time CART KO mice spent in the light 
compartment; however, given our earlier results showing a potentiated corticosterone 
response in acutely restrained CART KO mice, one might presume that the increases in 
anxiety (as evidenced by decreases in exploratory behaviors) and concomitant potentiated 
corticosterone response in CART KO mice may be masking any genotype differences in 
anxiety (as evidenced by the increase in light time) such that the corticosterone levels in 
CIE treated mice are similar.  That is to say, if CART KO mice are experiencing an 
intermediate level of anxiety compared to WT mice, the potentiated endocrine response 
may be raising corticosterone levels of CART KO mice to approximately match those of 
WT mice.  Further studies, however, would be required to examine this possibility. 
Electrophysiologically, we found that acute application of CART peptide onto 
central amygdala neurons of ethanol naïve mice had no effect on mEPSC frequency or 
amplitude, indicating that CART peptide does not have a postsynaptic effect on AMPA 
receptor-mediated transmission.  The lack of a CART peptide effect on mEPSC 
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frequency also indicates that CART peptide has no presynaptic actions.  We did, 
however, observe a significant effect of CART peptide application on AMPA/NMDA 
ratios such that the ratio was decreased. When taken together with our mEPSC data and 
the previous literature showing that CART does not affect AMPA receptor-mediated 
neurotransmission, we can infer that the observed effect of CART peptide on 
AMPA/NMDA ratios was mediated by a relative increase in NMDA receptor-mediated 
currents.  This finding is in accord with previous studies showing that CART peptide 
enhances NMDA receptor-mediated neurotransmission (Dun et al., 2006; Hsun Lin et al., 
2005).  Furthermore, when considered alongside the finding that CART peptide was 
increased in the central amygdala during ethanol withdrawal (Dandekar et al., 2008a), 
this CART peptide-mediated enhancement of central amygdala glutamatergic signaling 
may represent the cellular mechanism through which CART peptides exert their 
anxiogenic effects in vivo and support our overall hypothesis that CART peptide-
mediated increases in glutamatergic signaling modulate ethanol withdrawal-induced 
anxiety.   
Examination of the spontaneous excitatory postsynaptic currents from mice in the 
chronic intermittent ethanol study revealed no genotype or CIE effects on sEPSC 
frequency; however, we did observe a significant increase in the average event 
amplitudes in the CIE treated mice of both genotypes.  Given that these sEPSCs were 
collected at -80 mV (at which the Mg
2+
 block on NMDA receptors should be intact) and 
that these currents were DNQX-sensitive (an AMPA receptor antagonist), we can assume 
that the currents were strictly AMPA receptor-mediated and that the effects of CIE were 
specifically on postsynaptic AMPA receptors.   
We found no differences in the AMPA/NMDA ratios in any of the treatment 
groups.  Given our finding that CIE treatment increased AMPA receptor-mediated sEPSC 
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amplitudes, we might expect an increase in the AMPA/NMDA ratios of CIE-treated 
mice.  One possibility for the lack of an observed difference in the AMPA/NMDA ratios 
between treatment groups is that there was an undetected concomitant increase in NMDA 
receptors such that any potential increase in AMPA receptor-mediated transmission was 
countered by an increase in NMDA receptors, thus leaving the relative ratio of AMPA to 
NMDA receptors unchanged.  Increases in NMDA receptor function and/or subunit 
expression are among the most common neuroadaptations brought about by chronic 
ethanol treatments (Chandler et al., 1993; Hendricson et al., 2007; Kalluri et al., 1998; 
Kroener et al., 2012; Lack et al., 2007; Roberto et al., 2006; Trevisan et al., 1994; Wang 
et al., 2012).  Despite this, we did not directly measure NMDA receptor-mediated 
currents or expression in the current study so we cannot confirm any speculation apropos 
our observed AMPA/NMDA ratio results.   
We also examined paired pulse ratios in mice from the CIE experiments at 25, 50, 
and 250 millisecond interstimulus intervals.  Increases in the paired pulse ratio are 
thought to reflect a decrease in presynaptic release probability, while decreases in PPR 
are thought to represent an increase in presynaptic release probability.  We observed a 
significant increase in PPR25 and a statistical trend towards an increase in PPR250 in 
wild type CIE-treated mice.  This decrease in presynaptic release probability was absent 
in all of the other treatment groups and thus may reflect a unique CART peptide-
dependent neuroadaptation that contributes to either (or both) the enhanced ethanol intake 
or the increased anxiety-like behaviors observed in WT mice. 
Our behavioral and electrophysiological findings are in accord with a number of 
studies demonstrating chronic ethanol and withdrawal effects on anxiety-like behaviors 
and AMPA receptor-mediated currents.  Lack et al. (2007) found that 12 hours per day of 
ethanol vapor exposure for ten consecutive days resulted in increased anxiety-like 
 109 
behaviors in rats immediately following their final ethanol exposure, as well as, following 
24 hours of withdrawal.  Similar to our findings, this group found significant decreases in 
exploratory rearing and compartment transition behaviors during withdrawal.  
Corresponding to these increased anxiety-like behaviors, they also found increased 
sEPSC amplitudes in basolateral amygdala neurons from Sprague-Dawley rats 
immediately following the final ethanol vapor exposure and mEPSC amplitudes 
following 24 hours of withdrawal.  They finally demonstrated that the observed increases 
in anxiety-like behaviors were AMPA receptor-dependent by microinjecting DNQX 
bilaterally into the basolateral amygdala and showing a decrease in anxiety-like 
behaviors.  A subsequent study from the same group found an increase in asynchronous 
EPSC (aEPSCs) amplitudes in rats after 24 hours of withdrawal, but not in rats that did 
not undergo withdrawal (Christian et al., 2012).  This effect may have been caused by 
concomitant increases in the surface expression of GluA1 and GluA2/3 AMPA receptor 
subunits.  These aEPSCs were also found to be DNQX-sensitive, demonstrating that they 
were mediated exclusively by AMPA receptors.   
Several studies have described in vivo chronic ethanol (and withdrawal) 
treatment-induced increases in AMPA receptor function or expression.  Haugbol et al. 
(2005) found that after 84 hours of continuous ethanol exposure and 12 hours of 
withdrawal, AMPA receptor binding in the cerebrum increased 94% above control levels.  
Wang et al. (2012) found that chronic ip ethanol injections increased synaptic protein 
levels of the AMPA receptor subunits, GluR1 and GluR2, relative to saline-treated 
control mice in the dorsal medial striatum (DMS).  This same study found that inhibition 
of AMPA receptors in the DMS reduced operant self administration of ethanol but not 
sucrose.  Marty and Spigelman (2012) found that a chronic intermittent ethanol treatment 
paradigm produced an enhancement of AMPA receptor mEPSC amplitudes in the 
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nucleus accumbens core, ostensibly due to a CIE-induced increase in GluA2 lacking 
AMPA receptors.  A recent study from our lab found that a single three day bout of CIE 
in adolescent mice resulted in a metaplastic shift from LTD to LTP in AMPA receptor-
mediated EPSCs (Jeanes et al., 2012).  Further studies have found that in vivo modulation 
of AMPA receptors exert significant effects on ethanol consumption.  For example, 
subcutaneous administration of topiramate, which is known to act as an antagonist at 
AMPA & kainite glutamate receptors, dose-dependently decreased ethanol consumption 
in a two bottle choice drinking paradigm (Nguyen et al., 2007).  Another group found that 
enhanced AMPA receptor activity could facilitate ethanol consumption (Cannady et al., 
2012).  This group found that pretreatment of alcohol preferring rats with aniracetam, a 
positive allosteric modulator of AMPA receptors, increased operant pressing for ethanol 
compared to control groups.  They further demonstrated the AMPA receptor specificity 
of the effect by abolishing the effect with DNQX treatment. 
Taken together, our data support the following conclusions: (1) CART peptide 
enhancement of NMDA receptor-mediated currents in the central amygdala may be the 
mechanism of action mediating its anxiogenic effects, (2) a putative role for aberrant pre- 
and postsynaptic neuroadaptations of central amygdala AMPA receptor-mediated 
neurotransmission in ethanol withdrawal-induced anxiety and alcoholism, and (3) a role 
for CART peptide as a modulator of CIE-induced increases in ethanol consumption and 
withdrawal-induced anxiety behaviors.  
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Chapter 4:   
Concluding remarks and future studies 
These studies were undertaken in an attempt to elucidate the role of CART 
peptides in addiction and alcoholism in particular.  The distribution of CART peptides 
and results from behavioral pharmacology experiments posit a role for CART peptides in 
the modulation of aberrant or excessive dopamine signaling (e.g. in response to 
administration of drugs of abuse).  Specific lines of evidence supporting that idea include 
the findings that administration of psychostimulants or ethanol, both of which increase 
dopamine levels in the nucleus accumbens (Di Chiara and Imperato, 1988; Weiss et al., 
1993), increase CART mRNA and peptide expression (Douglass et al., 1995; Hunter et 
al., 2005; Salinas et al., 2006) in the nucleus accumbens.  Ultrastructural analyses have 
shown that CART peptide colocalizes with GABA presynaptically and synapses 
containing both form functional synapses onto accumbal (Smith et al., 1997) and ventral 
midbrain neurons (Dallvechia-Adams et al., 2002).  Thus, it is possible that in response to 
increases in dopamine signaling, CART peptide levels are increased, and released 
synaptically onto accumbal and midbrain neurons.  Given the nature of the putative 
CART receptor (i.e. Gi/o), it is possible that its activation would result in an inhibitory 
effect (Jones and Kuhar, 2008; Vicentic et al., 2006).  Indeed, intra-accumbal injection of 
CART peptide was found to blunt the effect of subsequently administered 
psychostimulants to increase locomotor activity (Jaworski et al., 2003; Kim et al., 2003).  
Furthermore, intra-PVT injections with either TTX or CART peptide were shown to 
inhibit cocaine-primed reinstatement – a behavior thought to be mediated by dopamine 
signaling (James et al., 2010).  Presumably this effect was due to negative modulation of 
PVT efferents, which have been previously shown to enhance dopamine release in the 
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NAc (Parsons et al., 2007).  Finally, CART peptide was shown to inhibit L-type calcium 
channels in hippocampal neurons (Yermolaieva et al., 2001).  Despite these inhibitory 
effects, CART peptide injections into the VTA (and to a lesser extent the substantia 
nigra) were found to increase locomotor activity in a haloperidol-sensitive (D2 
antagonist)  manner (Kimmel et al., 2000).  This study also found that intra-VTA CART 
peptide administration induced a conditioned place preference, suggesting that CART 
peptide itself may be reinforcing.  Seemingly, the psychostimulant-like actions of CART 
peptide argue against the hypothesis that CART peptides function as a homeostatic 
regulator of dopamine signaling in response to drugs of abuse.  However, these 
psychostimulant-like effects may be mediated by CART peptide inhibition of 
GABAergic interneurons in the VTA and subsequent disinhibition of dopaminergic 
neurons.  Indeed, approximately 70% of CART peptide containing synaptic terminals in 
the VTA appose GABAergic interneurons (Dallvechia-Adams et al., 2002).  Further 
supporting these results are the findings that icv or intra-VTA injections of CART 
peptide increase the concentrations of dopamine or its metabolites, DOPAC & HVA, in 
the nucleus accumbens (Kuhar et al., 2005; Shieh, 2003; Yang et al., 2004).  It should be 
noted that under normal conditions, the levels of CART peptide administered in these 
studies would never be reached unless stimulated by external events (e.g. drug 
administration) and that these studies were focused on specific brain region effects of 
CART peptide, neglecting the fact that CART peptides do not normally act at a single 
brain region at a time.   
Further obfuscating a clear role for CART peptides in the dopamine system are 
studies from CART KO mice which have demonstrated complete suppression or 
attenuation of psychostimulant induced behaviors acutely (increased locomotor activity) 
and chronically (locomotor sensitization) (Couceyro et al., 2005; Moffett et al., 2006).  
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This group further found that cocaine self administration was also reduced in CART KO 
mice.  Our lab’s contribution to this stew came in the form of a report showing a 
reduction in ethanol consumption in CART KO mice (Salinas et al., 2012).  The 
collective finding is that CART KO mice may find drugs of abuse to be less reinforcing 
or rewarding than WT mice.  This conclusion may have been foreshadowed by the 
previously mentioned ability of intra-VTA CART peptide to produce increased 
locomotor activity and a conditioned place preference.  As before, however, it should be 
noted that conditions of complete loss of CART peptide are unlikely and that the effects 
of removing the CART gene from mice may result in unforeseen compensatory events.  It 
would be interesting to examine if psychostimulants and ethanol can still induce increases 
in dopamine dialysates in the NAc of CART KO mice.  Given their decreased propensity 
to self administer or consume normally reinforcing drugs of abuse, one might expect a 
reduction or suppression of accumbal dopamine in response to a drug challenge.  It would 
also be interesting to examine the ability of a non-drug reinforcer like sucrose to increase 
accumbal dopamine given that CART KO and WT mice do not differ in their 
consumption or preference for it.  In all, we can safely presume a role for CART in the 
dopamine system; that role, however, is still unclear and likely to remain so until the 
putative CART receptor can be cloned and specific modulators for said receptor found 
and made available for research. 
Fueled by my interest in anxiety and stress, I decided to spend the final portion of 
my studies investigating the effects of chronic intermittent ethanol (CIE) vapor exposure 
on withdrawal-induced anxiety and whether there would be any differences between 
CART KO and WT mice.  Given the role of CART peptides in anxiety and stress, I 
hypothesized that CART KO mice would have attenuated levels of anxiety and a blunted 
stress response compared to WT mice during withdrawal.   
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These studies would be the first to examine anxiety and stress in CART KO mice, 
as well as, the first from our lab to examine anxiety-like behaviors.  Thus it was 
necessary to conduct a few control experiments.  I began by testing the behavioral 
apparatus (light/dark box) with WT mice exposed to either a clean novel cage (handling 
control) or a mild restraint stress and examining anxiety-like behaviors and plasma 
corticosterone content.  The results from this experiment validated the light/dark box in 
our hands for detecting differences in anxiety-like behaviors and our ability to detect 
changes in plasma corticosterone content related to anxiety behaviors.  Given the 
anxiogenic properties of CART, one might expect that basal anxiety levels would differ 
between CART KO and WT mice.  They did not.  We then compared stress responses 
between genotypes in response to a mild restraint stress.  We expected that there would 
be an attenuation of anxiety-like behaviors and plasma corticosterone in response to a 
stressor in CART KO mice.  Behaviorally, we observed no differences in anxiety-like 
behaviors between genotypes.  Plasma corticosterone content, however, was significantly 
higher in CART KO mice than in WT mice when exposed to a stressor.  This result was 
surprising and could not have been predicted by reports in the literature.   
The lack of behavioral differences under basal and acutely stressed conditions 
was welcomed as it seemed to suggest a normal basal function of anxiety and stress 
systems in CART KO mice – of concern was the potentiated corticosterone response.  
This finding may reflect a dysregulation of the HPA axis in CART KO mice and suggests 
that CART peptides are required for normal HPA axis function.  Potentially related to 
this point is a study of an Italian family with a known CART gene polymorphism.  It was 
reported that adolescents from this family carrying the CART gene polymorphism 
exhibited increased anxiety and depression relative to their family members not carrying 
the mutation (Miraglia del Giudice et al., 2006).  This CART gene polymorphism in vitro 
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was shown to result in dysfunctional processing and decreased release of CART peptides 
(Dominguez et al., 2004).  It was subsequently shown that the mutation also resulted in a 
deficiency of bioavailable CART peptide in humans (Yanik et al., 2006).  Given the 
similar phenotype (i.e. hypo-CART function/levels), one could expect that the people 
with the CART gene polymorphism might have a similar, potentiated corticosterone 
response to mild stressors.  If this held true, then perhaps the observed depression might 
be the result of a dysfunctional HPA axis that overreacts to everyday mild stressors, 
resulting in chronic abnormally elevated circulating corticosterone levels.  Indeed, in 
preclinical studies, chronic stress paradigms are often used to mimic some aspects of 
clinical depression including consistently elevated circulating cortisol (corticosterone 
analog in humans) levels (Tafet and Bernardini, 2003).  A more comprehensive study of 
stress in CART KO mice would be required to determine if this hypothesis holds water.  
The first experiment would involve determining how long corticosterone levels in acutely 
restrained CART KO and WT mice remain elevated following the stressor.  Then a 
second experiment would involve chronically stressing CART KO mice and determining 
if a depression-like phenotype could be more readily induced than in WT mice.  This 
study would be completed by a final experiment aimed at determining if HPA axis 
responsivity is altered in chronically stressed CART KO mice; that is to say, would 
circulating corticosterone levels be elevated under basal conditions in chronically stressed 
mice and would the corticosterone response still be potentiated in response to a stress 
challenge in chronically stressed mice?  The answers to these questions may not 
necessarily be relevant to alcoholism but certainly might have an impact on the treatment 
of clinical depression or anxiety disorders.  If in fact, hypofunction of CART peptide in 
humans contributes to the development or expression of depression (outside of those 
people with the aforementioned CART gene polymorphism) in the general population, 
 116 
then CART peptides should be explored as an anti-depressant treatment.  Given the 
ability of CART peptides to readily pass the blood-brain-barrier, the treatment might 
consist of a slightly a modified version of the CART peptide to aid against degradation 
by endoproteases. 
Following a single bout of CIE, we found enhanced ethanol consumption in mice 
of both genotypes relative to air treated controls with statistical trends towards a 
reduction in ethanol consumption in CART KO mice compared to WT mice and an 
additional statistical trend towards reduced ethanol consumption in CIE treated CART 
KO mice relative to CIE treated WT mice.  Some of these results were expected and 
others were not.  In the former category was the lack of a genotype effect on ethanol 
consumption.  We have previously observed reduced ethanol consumption in CART KO 
mice in an unlimited access paradigm.  The mice in these experiments were on a limited 
access paradigm and thus had a driving force to increase ethanol consumption.  This 
effect led to approximately matched levels of ethanol consumption between CART KO 
and WT mice overall.  Unfortunately, we did not observe any differences in anxiety-like 
behaviors after one bout of CIE between genotypes.  There was, however, a significant 
decrease in exploratory behaviors in CIE treated mice of both genotypes – evidence of 
increased anxiety. 
Following a second bout of CIE treatment, we again observed decreases in 
exploratory behaviors in mice of both genotypes, as well as, other behaviors indicating a 
reduction in anxiety in CART KO mice.  Taken together, it appears that CART KO mice 
have reduced anxiety relative to their WT counterparts following two bouts of CIE or Air 
treatment.  It is possible that the hypothesized reductions in anxiety in CART KO mice 
required chronic stress conditions (i.e. the repeated handling and injections associated 
with CIE treatment) to be revealed.  This idea, however, is not directly supported by the 
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corticosterone levels observed.  The corticosterone levels show approximately equal 
increases in CIE treated mice of both genotypes.  One potential explanation is that the 
previously observed potentiated corticosterone response is still in effect here such that 
though experiencing decreased anxiety relative WT mice, the CART KO mice have 
enhanced corticosterone levels to approximately match those levels found in the WT 
mice. 
The final components of this study examined glutamatergic neurotransmission in 
the central amygdala in response to acute CART peptide application and following two 
bouts of CIE and early (~6.5 hours) withdrawal.  This study, to our knowledge, is the first 
to examine chronic intermittent ethanol vapor exposure effects in central amygdala 
neurons.  It is also the first study, to our knowledge, to examine ethanol consumption, 
withdrawal-induced anxiety behaviors, and electrophysiological properties in the same 
adult mice.   
Our first result was that CART peptide led to a decrease in AMPA/NMDA ratios.  
Given that CART peptide had no effect on AMPA receptor-mediated transmission 
otherwise, we presume that the effect was strictly NMDA receptor-mediated.  This is in 
accord with the literature showing CART peptide-induced enhancement of NMDA 
receptor mediated currents in spinal cord preparations (Dun et al., 2006; Hsun Lin et al., 
2005). 
Following two bouts of CIE treatment, we found increased sEPSC amplitudes in 
CART KO and WT mice.  This result suggests that CIE leads to an enhancement of 
postsynaptic AMPA receptor-mediated neurotransmission in the CeA.  Presynaptically, 
we found that CIE treatment increased the paired pulse ratio of WT mice suggesting a 
decrease in presynaptic release probability.  This finding was unique to CIE-treated WT 
mice and may contribute to the observed differences in anxiety between CIE-treated 
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CART KO and WT mice.  The most similar studies in the CeA to our own have been 
conducted immediately following the termination of the ethanol exposure and found that 
pharmacologically-isolated AMPA receptor-mediated currents were reduced at higher 
stimulus intensities (Roberto et al., 2004b); however, it should be noted that these 
animals never underwent withdrawal and any concomitant changes in neurobiology 
associated with ethanol withdrawal.  Our studies, on the other hand, were designed to 
coincide with peak withdrawal-induced hyperexcitability as determined by peak 
handling-induced convulsion scores (Becker and Hale, 1993).  Studies in a neighboring 
region, the BLA, conducted after 24 hours of withdrawal did have similar findings to our 
own postsynaptically, but not presynaptically (Christian et al., 2012; Lack et al., 2007).  
There are several differences between our studies, but I believe the most notable are the 
difference in withdrawal time, the fact that their studies used rats, and the fact that their 
studies were conducted in juveniles.  Any of these could potentially account for the 
differences in presynaptic release probability observed in our studies.  It appears that 
CART KO mice had reduced withdrawal-induced anxiety compared to CART WT mice.  
If we were to try and match our electrophysiology results with this behavior, the most 
likely candidate would be our finding that presynaptic release probability was reduced in 
CIE-treated WT mice only.  However, since mice of both genotypes exhibited decreased 
exploratory behaviors following CIE treatment, one could speculate that perhaps 
behaviors that are exploratory in nature are governed by AMPA receptor-mediated 
neurotransmission in the CeA.  An alternative explanation for this result could be 
glucocorticoid-mediated enhancement of glutamatergic neurotransmission and, in 
particular, increased membrane trafficking of AMPA receptors (Liu et al., 2010; Yuen et 
al., 2009; Yuen et al., 2011). 
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Taken all together, these studies have demonstrated that CART peptides:  (1) 
enhance NMDA receptor-mediated currents, (2) play a role in ethanol appetitive 
behaviors, (3) regulate the normal function of the HPA axis in response to an acute 
stressor, (4) may modulate CIE-induced increases in ethanol consumption, (5) reduce 
anxiety-like behaviors during early withdrawal from CIE, and (6) contribute to 
presynaptic alterations in glutamatergic neuroadaptations induced by CIE.   
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